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The misuse and abuse of  controlled prescription 
medication is a significant and growing problem in 
the United States.  The National Survey on Drug 
Use and Health (NSDUH) estimates that in 2012, 
20.9 percent of  the United States’ population 12 
years of  age or older had used prescription-type 
psychotherapeutics illicitly during their lifetime 
while 2.6 percent had done so in the past 30 days 
(SAMHSA, 2013).  Opioid pain relievers are 
the most commonly abused type of  controlled 
prescription medication followed by central nervous 
system depressants, and central nervous system 
stimulants (SAMHSA, 2013).  Data suggest that 
the rate of  controlled prescription medication 
abuse is being driven by the high rates at which 
these medications are currently being prescribed 
(Compton & Volkow, 2006; Fortuna, Robbins, 
Caiola, Joynt, & Halterman, 2010; Kuehn, 2007; 
Manchikanti & Singh, 2008; Maxwell, 2011).  
One potential approach to curtailing the abuse 
of  controlled prescription medication is through the 
implementation of  prescription drug monitoring 
programs (PDMPs) (Manchikanti, Whitfield, & 
Pallone, 2005; Wang & Christo, 2009).  A PDMP 
is a statewide electronic database which collects 
designated data on substances dispensed in the 
state.  A PDMP is housed by a specified statewide 
regulatory, administrative or law enforcement 
agency.  The housing agency distributes data from 
the database to individuals who are authorized under 
state law to receive the information for purposes of  
their profession (National Alliance for Model State 
Drug Laws, 2011).
Established in its present form in 2004, the 
Indiana Scheduled Prescription Electronic Collection 
and Tracking Program (INSPECT) is Indiana’s 
PDMP.  The Indiana Professional Licensing Agency 
(IPLA; http://www.in.gov/pla/) and the Indiana 
Board of  Pharmacy designed INSPECT to serve 
as a tool to address the problem of  prescription 
drug abuse and diversion in Indiana.  INSPECT 
collects and retains in its database every controlled 
substance dispensed on an outpatient basis by all 
licensed pharmacies in the state.  INSPECT performs 
two critical functions:  it maintains a warehouse of  
patient information for health care professionals 
and it provides an important investigative tool for 
law enforcement.  Only registered licensed providers 
who dispense and/or prescribe medication have 
on-going access to INSPECT.  At the time the 
IPLA INSPECT Knowledge and Use Survey was 
completed, Indiana law did not require medical 
providers or pharmacists to review INSPECT prior 
to prescribing or dispensing controlled substances; 
however, IPLA encouraged such reviews.  As of  
December 15, 2013, medical providers treating 
chronic non-terminal pain patients with opioids 
are required to check INSPECT at a patient’s initial 
visit and then at least annually (Indiana General 
Assembly, 2013). Access to INSPECT can be granted 
to law enforcement if  there is an active investigation 
involving prescription drug misuse/abuse and the 
agent is registered with IPLA.  
The development of  the IPLA INSPECT 
Knowledge and Use Survey was a collaborative 
effort between representatives from IPLA, the State 
Prescription Drug Abuse Prevention Task Force 
Education Committee, and the Indiana University 
Purdue University – Indianapolis (IUPUI) Center 
In order to participate in the survey, potential 
respondents had to hold a valid license to prescribe 
and/or dispense controlled substances in Indiana 
and not be Doctors of  Veterinary Medicine.  The 
IPLA identified 38,333 individuals licensed as 
Medical Doctors (MDs), Doctors of  Osteopathy 
(DOs), Doctors of  Podiatric Medicine (DPMs), 
Physician Assistants (PAs), Nurse Practitioners 
(NPs), Dentists, or Pharmacists who held valid 
controlled substance prescribing and/or dispensing 
privileges in Indiana.  At the request of  the CHP, 
for Health Policy (CHP).   The web-based survey 
was designed to gather information on prescribers’ 
and dispensers’ knowledge, use, and opinions of  
INSPECT as well as to assess prescribers’ and 
dispensers’ attitudes and beliefs about prescribing and 
dispensing opioids.
IPLA sent an initial electronic invitation and three 
follow-up reminders to complete the INSPECT 
survey to all 38,333 eligible practitioners.  Data 
collection began on October 15, 2013 and ended 
on November 30, 2013.  Of  the 38,333 eligible 
practitioners, a total of  5,994 finished the survey 
yielding an overall response rate of  15.6%.  NPs, 
Dentists, and PAs responded at rates that were 
slightly higher than the remaining license types (see 
Table 1).  
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Table 1. IPLA INSPECT Survey Response Rate
Licensure Type Number Invited Number who 
Completed Survey
Response 
Rate
Medical Doctor (MD) 17,395 2,204 12.7%
Doctor of  Osteopathy (OD) 1,395 191 13.7%
Doctor of  Podiatric Medicine (DPM) 347 49 14.1%
Physician Assistant (PA) 905 181 20.0%
Nurse Practitioner (NP) 3,822 886 23.2%
Dentist (DDS or DMD) 3,717 753 20.3%
Pharmacist (Pharm D or Pharm BS) 10,606 1,582 14.9%
Other/Missing -- 148 --
 Total 38,333 5,994 15.6%
The IPLA INSPECT Knowledge and Use 
Survey covered the following topics:  practice 
characteristics; demographics; knowledge and use 
of  INSPECT; barriers related to use of  INSPECT; 
administration and use of  INSPECT’s data; impact 
of  INSPECT on prescribing and dispensing 
behavior; views on prescription drug abuse; 
management of  patients with chronic, non-terminal 
pain; knowledge of  the risks and benefits of  using 
opioids for the treatment of  chronic, non-terminal 
pain; and additional comments and suggestions.  
The survey questions each respondent was eligible 
to answer varied based on their responses to a set 
of  screening questions so that not all respondents 
answered all questions.
Although 5,994 individuals finished the survey, 
many respondents chose not to answer all the 
survey questions they were eligible to answer, 
resulting in varying amounts of  missing data.   The 
tables in the report will present the total population 
of  individuals who were eligible to answer a given 
question, the total number of  individuals who were 
eligible to answer a given question but did not, and 
then the percentages based on the actual individuals 
who did complete the question.  The percentages 
cited in the text also refer to the population of  
respondents who completed a given question.   
Throughout this report, we focus the readers’ 
attention on patterns in the data that are statistically 
significant at the p<.05 level or better.
Practice Characteristics
The first section of  the survey asked respondents 
to provide information regarding both their 
professional and demographic background and their 
professional practice.  Respondents were asked to 
provide their license information and the majority 
of  respondents who did so described themselves as 
being licensed MDs (37.4%) or licensed Pharmacists 
(26.9%).  The remaining respondents said they held 
licenses as NPs (15.0%), Dentists (12.8%), DOs 
(3.2%), PAs (3.1%), DPMs (0.8%), or held some 
other license (0.7%).  The survey asked MDs, DOs, 
PAs, and NPs to provide their medical specialty. The 
majority of  respondents in these professions stated 
they practiced either Family Medicine (37.4%) or 
Internal Medicine (14.9%).  
All respondents were asked to describe the type of  
setting where they saw the majority of  their patients.  
Of  survey participants who chose to respond, most 
said they worked in an outpatient clinic (37.7%), a 
pharmacy (15.0%), an inpatient hospital (14.3%) or 
in some other setting such as in academic research, 
a university health clinic, a mental health center, a 
correctional facility, a dental clinic, in a nursing home, 
or were retired or and no longer practicing (12.1%; 
see Table 2).  
Survey participants, other than Pharmacists, were 
asked to specify whether they worked primarily with 
adults, children, or both.  Respondents who chose to 
answer typically said they worked with adults (42.7%) 
or with adults and children (49.1%).  
When asked to indicate whether they served 
patients living in states other than Indiana, 49.7% of  
respondents who completed the question said they 
did, 45.8% of  respondents said they did not, and 
4.5% of  respondents were unsure whether or not 
they served patients living in other states. 
 Respondents reported having been practicing 
in their primary field for 18.9 years on average (SD 
= 12.9; see Table 2).  Although all individuals who 
participated in the survey held a valid license to 
prescribe or dispense controlled substances, the 
survey did not ask participants to indicate whether 
they were actively practicing within their profession. 
 
Demographic Characteristics
In terms of  gender, 54.0% of  survey participants 
reported being male and 46.0% of  participants 
reported being female.  Racially, most respondents 
said they were Caucasian (88.5%) with the remaining 
respondents stating they were Asian (4.9%), of  
another race (3.0%), African-American (2.3%), or 
Latino (1.2%).  The average age of  respondents was 
50.4 years (SD = 12.8; see Table 2).  
6Table 2. Practice and Demographic Characteristics of  Sample
Practice Indicators N %
License Type
Number Eligible 5,994
Eligible Did not Respond 106
Total Number of  Responses 5,888
 Medical Doctor 2,204 (37.4)
 Doctor of  Osteopathy 191 (3.2)
 Doctor of  Podiatric Medicine 49 (0.8)
 Physician Assistant 181 (3.1)
 Nurse Practitioner 886 (15.0)
 Dentist 753 (12.8)
 Pharmacist 1,582 (26.9)
 Other 42 (0.7)
Primary Practice Type
Number Eligible 4,306
Eligible Did not Respond 143
Total Number of  Responses 4,163
 Adult 1,779 (42.7)
 Pediatric 338 (8.1)
 Both 2,046 (49.1)
Primary Practice Setting
Number Eligible 5,994
Eligible But No Response 227
Total Number of  Responses 5,767
 Community Health Center/Public Health Clinic 392 (6.8)
 Diagnostic Testing Facility 13 (0.2)
 Emergency Room 334 (5.8)
 Hospital (Inpatient) 826 (14.3)
 Long Term Acute Care Hospital 42 (0.7)
 Outpatient Clinic (Private Practice or Academic) 2,175 (37.7)
 Outpatient Surgery Center 40 (0.7)
 Pain Management Clinic 49 (0.8)
 Pharmacy (Inpatient) 105 (1.8)
 Pharmacy (Outpatient) 866 (15.0)
 Rehabilitation Hospital 5 (0.1)
 Retail Medicine Clinic 94 (1.6)
 Substance Abuse Treatment Facility (Inpatient) 2 (0.0)
 Urgent Care Facility 124 (2.2)
 Other 700 (12.1)
7Table 2 Cont.  Practice and Demographic Characteristics of  Sample
N (%)
Prescribed controlled substances in past 12 mos.
Number Eligible 4,306
Eligible But No Response 9
Total Number of  Responses 4,297
 Yes 3,783 (88.0)
 No 514 (12.0)
Dispensed controlled substances in past 12 mos.
Number Eligible 5,994
Eligible But No Response 179
Total Number of  Responses 5,815
 Yes 2,145 (36.9)
 No 3,670 (63.1)
Years in Practice M (SD)
Number Eligible 5,994
Eligible But No Response 164
Total Number of  Responses 5,830
 5 years or less 1154 (19.8)
 6-10 years 785 (13.5)
 11-19 years 1184 (20.3)
 20-29 years 1278 (21.9)
 30-39 years 1018 (17.5)
 40 years or more 411 (7.0)
M (SD)
18.9 (12.9)
Demographic Indicators N (%)
Gender
Number Eligible 5,994
Eligible But No Response 218
Total Number of  Responses 5,776
 Male 3,121 (54.0)
 Female 2,655 (46.0)
Race
Number Eligible 5,994
Eligible But No Response 248
Total Number of  Responses 5,746
 Asian 281 (4.9)
 African-American 135 (2.3)
 Caucasian 5,088 (88.5)
 Latino 67 (1.2)
 Other Race 175 (3.0)
Age
Number Eligible 5,994
Eligible But No Response 279
Total Number of  Responses 5,715
35 years or less 903 (15.8)
36-45 1186 (20.8)
46-55 1464 (25.6)
56 years or older 2162 (37.8)
M (SD)
50.4 (12.8)
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Prescribers and Dispensers
To aid in targeting questions specifically to 
participants who dealt with controlled substances, 
the survey had participants who held licenses 
which allowed them to prescribe medication (e.g., 
MDs, DOs, NPs, etc.; n = 4,412) indicate whether 
they prescribed any controlled substances in the 
past 12 months.  Eighty-eight percent (88.0%) of  
individuals with prescribing authority said they had 
prescribed controlled substances in the past 12 
months.  The survey similarly asked all respondents 
(N = 5,994) whether they had dispensed controlled 
medication in the past 12 months.  A total of  36.9% 
of  participants reported dispensing controlled 
substance medication in the past 12 months (see 
Table 2).  Table 2a provides a breakdown of  the 
demographic characteristics of  respondents who 
said they only prescribed controlled substance 
medications (n = 3,032), only dispensed controlled 
substance medications (n = 1,414) and who 
prescribed and dispensed controlled substance 
medications (n = 731).  A total of  474 respondents 
stated that they had neither prescribed nor dispensed 
controlled substance medication in the past 12 
months while the remaining 343 survey participants 
failed to provide sufficient data to determine their 
prescribing and/or dispensing patterns. Respondents 
who prescribed controlled substances or who 
prescribed and dispensed controlled substances were 
more likely to be MDs, NPs, and Dentists, were 
more likely to be male, and more likely to be older.  
Survey participants who only dispensed controlled 
substances were largely pharmacists (97.0%), were 
more often female (53.1%), and were somewhat 
younger than participants who had prescription 
privileges (see Table 2a).
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Prescribers Dispensers Prescribers  
and 
Dispensers
Did not 
Prescribe or 
Dispense
N (%) N (%) N (%) N (%) χ2 P
Licensure 5516.6 <.001
 Medical Doctor 1458 (48.1) 25 (1.8) 385 (52.7) 288 (60.8)
 Doctor of  Osteopathy 125 (4.1) 3 (0.2) 52 (7.1) 11 (2.3)
 Doctor of  Podiatric Medicine 43 (1.4) 0 (0.0) 1 (0.1) 4 (0.8)
 Physician Assistant 118 (3.9) 0 (0.0) 45 (6.2) 13 (2.7)
 Nurse Practitioner 663 (21.9) 1 (0.1) 128 (17.5) 83 (17.5)
 Dentist 566 (18.7) 2 (0.1) 107 (14.6) 60 (12.7)
 Pharmacist 0 (0.0) 1371 (97.0) 0 (0.0) 0 (0.0)
 Other 29 (1.0) 1 (0.1) 4 (0.5) 4 (0.8)
 Not provided 30 (1.0) 11 (0.8) 9 (1.2) 11 (2.3)
Practice Type 61.7 <.001
 Adult 1246 (41.1) 9 (0.6) 278 (38.0) 223 (47.0)
 Pediatric 228 (7.5) 1 (0.1) 46 (6.3) 61 (12.0)
 Both 1458 (48.1) 30 (2.1) 380 (52.0) 153 (32.3)
 Not Applicable - Pharmacists 0 (0.0) 1371 (97.0) 0 (0.0) 0 (0.0)
 Not provided 100 (3.3) 3 (0.2) 27 (3.7) 37 (7.8)
Gender 62.2 <.001
 Male 1636 (54.0) 622 (44.0) 423 (57.9) 275 (58.0)
 Female 1315 (43.4) 751 (53.1) 285 (39.0) 177 (37.3)
 Not provided 81 (2.7) 41 (2.9) 23 (3.1) 22 (4.6)
Race 54.0 <.001
 Asian 151 (5.0) 46 (3.3) 50 (6.8) 28 (5.9)
 African-American 67 (2.2) 23 (1.6) 28 (3.8) 10 (2.1)
 Caucasian 2595 (85.6) 1257 (88.9) 591 (80.8) 382 (80.6)
 Latino 33 (1.1) 8 (0.6) 9 (1.2) 14 (3.0)
 Other Race 98 (3.2) 28 (2.0) 23 (3.1) 12 (2.5)
 Not provided 88 (2.9) 52 (3.7) 30 (4.1) 28 (5.9)
Age 289.0 <.001
 35 years or less 357 (11.8) 372 (26.3) 96 (13.1) 34 (7.2)
 36-45 617 (20.3) 293 (20.7) 171 (23.4) 48 (10.1)
 45-55 812 (26.8) 292 (20.7) 200 (27.4) 100 (21.1)
 56 years or older 1133 (37.4) 401 (28.4) 233 (31.9) 265 (55.9)
 Not provided 113 (3.7) 56 (4.0) 31 (4.2) 27 (5.7)
Years in Practice 176.3 <.001
 5 years or less 595 (19.6) 278 (19.6) 187 (25.6) 66 (13.9)
 6-10 years 431 (14.2) 181 (12.8) 97 (13.3) 49 (10.3)
 11-19 years 686 (22.6) 223 (15.8) 167 (22.8) 76 (16.0)
 20-29 years 697 (23.0) 300 (21.2) 141 (19.3) 104 (21.9)
 30-39 years 480 (15.8) 287 (20.3) 93 (12.7) 103 (21.7)
 40 years or more 138 (4.6) 143 (10.1) 31 (4.2) 70 (14.8)
 Not provided 5 (0.2) 2 (0.1) 2 (0.3) 6 (1.3)
Note:  Pharmacists were not asked to describe their practice type.
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Knowledge and Use of  INSPECT
The survey asked respondents several questions 
related to their knowledge and use of  INSPECT.  
First, the survey had all respondents indicate 
whether they had ever heard of  INSPECT.  From 
the participants who chose to respond (n = 5,860), 
85.0% or 4,981 participants said they had heard 
of  INSPECT prior to receiving the survey. Table 
3 describes the percentage of  respondents who 
reported knowing about INSPECT by their license 
type where available.  Pharmacists, PAs, and NPs 
were significantly more likely than individuals 
with the remaining license types to report having 
heard of  INSPECT (see Table 3).  When compared 
to respondents who had heard of  INSPECT, 
respondents who had not heard of  INSPECT were 
more likely to have an exclusively adult (41.3%) 
or pediatric (13.3%) practice, were less likely to be 
pharmacists (10.0%), were more likely to report not 
prescribing (23.0%) or dispensing (74.7%) controlled 
substances in the past 12 months, were more likely to 
be male (66.0%),  were less likely to be white (79.7%), 
were more likely to be 56 years of  age or older 
(50.2%), and more likely to have been in practice for 
20 years or more (56.0%; see Table 3a).
Table 3.  Awareness of  INSPECT by License Type
Had heard of  INSPECT Had not heard of  INSPECT
N* (%) N* (%)
Medical Doctor 1,660 (76.9) 498 (23.1)
Doctor of  Osteopathy 151 (80.3) 37 (19.7)
Doctor of  Podiatric Medicine 35 (72.9) 13 (27.1)
Physician Assistant 167 (93.3) 12 (6.7)
Nurse Practitioner 810 (92.4) 67 (7.6)
Dentist 598 (80.7) 143 (19.3)
Pharmacist 1,469 (94.3) 88 (5.7)
Other 34 (85.0) 6 (14.9)
χ2 = 284.633, p<.000
*N will not total 5860 due to missing data
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Table 3a. Characteristics of  Respondents Who Had and Had Not Heard of  INSPECT
Had heard of  
INSPECT
Had not heard 
of  INSPECT
N (%) N (%) z p
Primary Practice Type
 Adult 1382 (27.7) 363 (41.3) 7.6 <.001
 Pediatric 215 (4.3) 117 (13.3) 7.6 <.001
 Both 1751 (35.2) 263 (29.9) 3.1 0.002
 Not Applicable - Pharmacists 1469 (29.5) 88 (10.0) 16.2 <.001
 Not provided 164 (3.3) 48 (5.5)
Prescribed Controlled Substances in the Past 12 Mos.
 Yes 3148 (63.2) 571 (65.0) 1.0 0.152
 No 300 (6.0) 202 (23.0) 11.6 <.001
 Not applicable - Pharmacists 1469 (29.5) 88 (10.0) 16.2 <.001
 Missing 64 (1.3) 18 (2.0)
Dispensed Controlled Substances in the Past 12 Mos.
 Yes 1910 (38.3) 201 (22.9) 9.8 <.001
 No 2951 (59.2) 657 (74.7) 9.5 <.001
 Missing 120 (2.4) 21 (2.4)
Practice Location
 Metro area 1 million or more 2387 (47.9) 367 (41.8) 3.4 <.001
 Metro area 250,000-1 million 736 (14.8) 122 (13.9) 0.7 0.240
 Metro area fewer than 250,000 808 (16.2) 111 (12.6) 2.9 0.004
 Non-metro 20,000+ adjacent to metro area 179 (3.6) 18 (2.0) 3.0 <.001
 Non-metro 20,000+ not adjacent to metro area 125 (2.5) 11 (1.3) 2.7 0.003
 Non-metro 2,500-19,999 adjacent to metro area 421 (8.5) 48 (5.5) 3.5 <.001
 Non-metro 2,500-19,999 not adjacent to metro area or 
completely rural
71 (1.4) 7 (0.8) 1.8 0.081
 Practice location not specified 254 (5.1) 195 (22.2)
Gender
 Male 2501 (50.2) 580 (66.0) 9.0 <.001
 Female 2354 (47.3) 272 (30.9) 9.6 <.001
 Not provided 126 (2.5) 27 (3.1)
Race
 Asian 203 (4.1) 76 (8.6) 4.6 <.001
 African-American 102 (2.0) 32 (3.6) 2.4 0.015
 Caucasian 4327 (86.9) 701 (79.7) 7.2 <.001
 Latino 50 (1.0) 16 (1.8) 1.7 0.089
 Other Race 144 (2.9) 26 (3.0) 0.2 0.873
 Not provided 155 (3.1) 28 (3.2)
Age
 <35 years 840 (16.9) 58 (6.6) 10.4 <.001
 36-45 1044 (21.0) 131 (14.9) 4.6 <.001
 45-55 1231 (24.7) 209 (23.8) 0.6 0.564
 56 and older 1691 (33.9) 441 (50.2) 9.0 <.001
 Not provided 175 (3.5) 40 (4.6)
Years in Practice
 5 years or less 1039 (20.9) 104 (11.8) 7.4 <.001
 6-10 years 676 (13.6) 101 (11.5) 1.8 0.075
 11-19 years 995 (20.0) 163 (18.5) 1.1 0.293
 20-29 years 1055 (21.2) 201 (22.9) 1.1 0.267
 30-39 years 806 (16.2) 189 (21.5) 3.6 <.001
 40 years or more 303 (6.1) 102 (11.6) 4.9 <.001
 Not provided 107 (2.1) 19 (2.2)
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Second, the survey asked those participants who had 
heard of  INSPECT (n = 4,981) to state whether 
or not they used it.  Of  the respondents who had 
heard of  INSPECT, 70.7% or 3,450 respondents 
said they had used INSPECT.  Table 4 displays the 
percentage of  respondents who reported using and 
not using INSPECT by their license type.  DOs 
were significantly more likely to have reported 
using INSPECT while Dentists and DPMs were 
significantly less likely to have reported using it 
when compared to respondents with the remaining 
license types (see Table 4).  When compared to 
respondents who used INSPECT, respondents who 
did not use INSPECT were more likely to report 
having a pediatric practice (9.5%), were likely to 
report not having prescribed (14.5%) or dispensed 
(64.3%) controlled substance medication, were more 
likely to be male (55.3%), were more likely to be 
older (42.0% were 56 years of  age or older), and were 
more likely to have been practicing in their field for a 
longer period of  time (30.7% had been practicing for 
30 years or more; see table 4a).
Table 4.  Use of  INSPECT by Type of  License
Had used INSPECT Had not used INSPECT
N* (%) N* (%)
Medical Doctor 1,148 (71.0) 469 (29.0)
Doctor of  Osteopathy 132 (89.2) 16 (10.8)
Doctor of  Podiatric Medicine 17 (51.5) 16 (48.5)
Physician Assistant 134 (80.7) 32 (19.3)
Nurse Practitioner 623 (78.3) 173 (21.7)
Dentist 292 (50.4) 287 (49.6)
Pharmacist 1,043 (71.8) 410 (28.2)
Other 24 (72.7) 9 (27.3)
χ2 = 176.236, p<.001
*N will not total to 4981 due to missing data
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Table 4a. Characteristics of  INSPECT Users and Non-Users
Had used 
INSPECT
Had not used 
INSPECT
N (%) N (%) z p
Primary Practice Type
 Adult 929 (26.9) 412 (28.8) 1.3 0.180
 Pediatric 78 (2.3) 136 (9.5) 8.8 <.001
 Both 1307 (37.9) 408 (28.5) 6.5 <.001
 Not Applicable - Pharmacists 1043 (30.2) 410 (28.7) 1.0 0.294
 Not provided 93 (2.7) 64 (4.5)
Prescribed Controlled Substances in the Past 12 Mos.
 Yes 2288 (66.3) 790 (55.2) 7.2 <.001
 No 83 (2.4) 207 (14.5) 12.5 <.001
 Not applicable - Pharmacists 1043 (30.2) 410 (28.7) 1.0 0.294
 Not provided 36 (1.0) 23 (1.6)
Dispensed Controlled Substances in the Past 12 Mos.
 Yes 1410 (40.9) 472 (33.0) 5.3 <.001
 No 1964 (56.9) 919 (64.3) 4.9 <.001
 Not provided 76 (2.2) 39 (2.7)
Practice Location
 Metro area 1 million or more 1667 (48.3) 676 (47.3) 0.6 0.525
 Metro area 250,000-1 million 486 (14.1) 234 (16.4) 2.0 0.044
 Metro area fewer than 250,000 595 (17.2) 194 (13.6) 3.2 0.001
 Non-metro 20,000+ adjacent to metro area 138 (4.0) 38 (2.7) 2.4 0.017
 Non-metro 20,000+ not adjacent to metro area 98 (2.8) 27 (1.9) 2.0 0.049
 Non-metro 2,500-19,999 adjacent to metro area 311 (9.0) 97 (6.8) 2.7 0.008
 Non-metro 2,500-19,999 not adjacent to metro area or 
completely rural
56 (1.6) 13 (0.9) 2.1 0.033
 Practice location not specified 99 (2.9) 151 (10.6)
Gender
 Male 1650 (47.8) 791 (55.3) 4.8 <.001
 Female 1712 (49.6) 605 (42.3) 4.7 <.001
 Not provided 88 (2.6) 34 (2.4)
Race
 Asian 134 (3.9) 65 (4.5) 1.0 0.348
 African-American 71 (2.1) 30 (2.1) 0.0 1.000
 Caucasian 3002 (87.0) 1239 (86.6) 0.4 0.708
 Latino 38 (1.1) 12 (0.8) 1.0 0.309
 Other Race 103 (3.0) 37 (2.6) 0.8 0.434
 Not provided 102 (3.0) 47 (3.3)
Age
 <35 years 641 (18.6) 195 (13.6) 4.5 <.001
 36-45 794 (23.0) 234 (16.4) 5.4 <.001
 45-55 863 (25.0) 349 (24.4) 0.7 0.459
 56 and older 1035 (30.0) 601 (42.0) 7.9 <.001
 Not provided 117 (3.4) 51 (3.6)
Years in Practice
 5 years or less 807 (23.4) 224 (15.7) 6.4 <.001
 6-10 years 518 (15.0) 151 (10.6) 4.3 <.001
 11-19 years 718 (20.8) 258 (18.0) 2.3 0.023
 20-29 years 707 (20.5) 322 (22.5) 1.5 0.124
 30-39 years 468 (13.6) 318 (22.2) 6.9 <.001
 40 years or more 166 (4.8) 122 (8.5) 4.5 <.001
 Not provided 66 (1.9) 35 (2.4)
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Next, the survey asked the respondents who 
had used INSPECT (n = 3,450) to report how 
long it had been since their last visit to INSPECT. 
The largest percentage of  INSPECT users (34.4%) 
said they had last visited INSPECT within the past 
week but not on the specific day they completed the 
survey (see Table 5).  
Fourth, the survey asked respondents specifically 
about how often they checked INSPECT for their 
patients who were on controlled substances.  Over 
three quarters of  INSPECT users (77.4%) said they 
checked INSPECT on a periodic basis for their 
patients on controlled substances with the remaining 
INSPECT users saying they checked INSPECT at 
every visit (8.6%), at some other interval (10.2%), 
or that they never checked INSPECT for patients 
on controlled substances (3.8%; see Table 5).  
Respondents who said they checked INSPECT 
periodically for patients on controlled substances 
were typically MDs (33.5%) or pharmacists (30.5%). 
The largest percentage of  periodic visitors to 
INSPECT reported having last visited INSPECT in 
the past week, but not on the day they completed the 
survey (36.7%; see table 5a).
The survey subsequently asked respondents 
who used INSPECT (n = 3,450) to indicate what 
best described their primary reason for checking 
INSPECT.  Most respondents stated that the main 
reason they had for checking INSPECT was to 
review a patient’s prescriptions (89.0%).  The survey 
also asked participants about several other common 
reasons they may have had to check INSPECT.  
Most survey participants who used INSPECT cited 
checking INSPECT for patients who they thought 
may be drug seeking (90.9%), for monitoring patients 
on controlled substances (61.4%), and for new 
patients prior to prescribing and/or dispensing a 
controlled substance (59.0%).  Table 5 describes the 
primary reason for which respondents stated that 
they used INSPECT as well as the other reasons 
respondents endorsed for accessing INSPECT.  
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Table 5. Frequency of  and Reasons for Checking INSPECT 
N (%)
When was the last time you visited INSPECT?
Number Eligible 3,450
Eligible But No Response 54
Total Number of  Responses 3,396
Today 431 (12.7)
In the past week, but not today 1,168 (34.4)
In the past month, but not in the past week 698 (20.6)
More than a month ago 930 (27.4)
Other 169 (5.0)
How often do you check INSPECT for patients on controlled substances?
Number Eligible 3,450
Eligible But No Response 61
Total Number of  Responses 3,389
At every visit 291 (8.6)
Periodically 2,622 (77.4)
Never 130 (3.8)
Other 346 (10.2)
Primary Reason for Checking INSPECT
Number Eligible 3,450
Eligible But No Response 114
Total Number of  Responses 3,336
Review a patient’s prescriptions 2,969 (89.0)
Review your prescription practices 45 (1.3)
Ensure the accuracy of  submitted data 96 (2.9)
To submit controlled substance data 106 (3.2)
Other primary reason 120 (3.6)
Other Reasons for Checking INSPECT
Number Eligible 3,450
Eligible But No Response 58
Total Number of  Responses 3,392
For new patients prior to prescribing and/or dispensing a controlled 
substance.
2,000 (59.0)
For established patients prior to prescribing and/or dispensing a new controlled substance. 1,470 (43.3)
For patients you think may be drug seeking. 3,084 (90.9)
To review your prescribing and/or dispensing practices. 459 (13.5)
To ensure the accuracy of  submitted data. 392 (11.6)
To monitor patients on controlled substances. 2,083 (61.4)
For other reasons 158 (4.7)
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Table 5a. INSPECT Users who Check INSPECT Periodically (n = 2,622)
N (%)
License Type
 Medical Doctor 879 (33.5)
 Doctor of  Osteopathy 110 (4.2)
 Doctor of  Podiatric Medicine 16 (0.6)
 Physician Assistant 113 (4.3)
 Nurse Practitioner 446 (17.0)
 Dentist 215 (8.2)
 Pharmacist 799 (30.5)
 Other 16 (0.6)
 Not provided 28 (1.1)
Last Time Visited INSPECT
 Today 283 (10.8)
 In the past week, but not today 962 (36.7)
 In the past month, but not in the past week 620 (23.6)
 More than a month ago 690 (26.3)
 Other 63 (2.4)
 Not provided 4 (0.2)
Use of  INSPECT by Controlled Substance 
Prescribers
The next set of  questions targeted the 2,288 
users of  INSPECT who said they had prescribed 
controlled substances in the past 12 months.  The 
survey asked these respondents for what percentage 
of  their patients on controlled substances  had 
they checked INSPECT in the past 30 days and in 
the past 12 months.  In terms of  30-day use, most 
INSPECT user-prescribers reported not checking 
INSPECT for any patients (20.0%), checking 
INSPECT for 1-10% of  their patients (28.2%) or 
checking INSPECT for 11-20% of  their patients 
(11.6%).  Regarding their use of  INSPECT in 
the past 12 months, most controlled substance 
prescribes reviewed INSPECT for 1-10% of  their 
patients (31.1%), reviewed INSPECT for 11-20% 
of  their patients (12.7%) or reviewed INSPECT 
for 91-100% of  their patients (13.0%; see Table 
6).  Tables 6a, 6b, and 6c break down INSPECT 
checking behavior for the past 30 days and the past 
12 months by practice type.  Most INSPECT user-
prescribers in pediatric practice reported checking 
INSPECT for 10.0% or less of  their patients on 
controlled substances at both 30 days (82.2%) and 
12 months (69.8%).  INSPECT user-prescribers 
who had an adult practice or who had a practice 
comprised of  both adult and pediatric patients 
reported checking INSPECT for their patients on 
controlled substances at rates similar to the overall 
sample of  INSPECT user-prescribers (see Tables 6a, 
6b, 6c).
Prescribers were then asked to consider the 
patients on whom they reviewed INSPECT in the 
past 12 months and indicate the percentage for 
whom the information from INSPECT altered their 
prescribing decision.  When considering the patients 
on whom they reviewed INSPECT in the past 12 
months, most respondents said that the information 
from INSPECT altered their prescribing decision for 
none of  their patients (16.7%) for 1-10% of  their 
patients (29.7%), or for 11-20% of  their patients 
(11.7%; see Table 6d).
Prescribers of  controlled substances who used 
INSPECT were also asked if  they had consulted 
INSPECT the last time they had considered writing 
a prescription for a controlled substance. Just 
over three quarters (37.0%) of  INSPECT-using 
prescribers stated that they had consulted it the 
last time they had considered writing a controlled 
substance prescription.  The survey asked this small 
percentage of  prescribers if  the information they 
learned from INSPECT prompted them to change 
their treatment plan. Just over half  of  the prescribers 
who had checked INSPECT (51.1%) made a change 
to their treatment plan based on what they learned 
from INSPECT while the remaining prescribers 
reported making no change to their treatment plan 
(49.9%) based on what they had learned (see Table 
6d).
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Table 6.  Use of  INSPECT by Controlled Substance Prescribers 
N (%)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 30 days?
Number Eligible 2,288
Eligible But No Response 56
Total Number of  Responses 2,232
 0% 447 (20.0)
 1-10% 630 (28.2)
 11-20% 258 (11.6)
 21-30% 179 (8.0)
 31-40% 107 (4.8)
 41-50% 73 (3.3)
 51-60% 105 (4.7)
 61-70% 62 (2.8)
 71-80% 81 (3.6)
 81-90% 78 (3.5)
 91-100% 212 (9.5)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 12 months?
Number Eligible 2,288
Eligible But No Response 46
Total Number of  Responses 2,242
 0% 159 (7.1)
 1-10% 697 (31.1)
 11-20% 285 (12.7)
 21-30% 187 (8.3)
 31-40% 118 (5.3)
 41-50% 86 (3.8)
 51-60% 103 (4.6)
 61-70% 68 (3.0)
 71-80% 130 (5.8)
 81-90% 117 (5.2)
 91-100% 292 (13.0)
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Table 6a. Use of  INSPECT by Controlled Substance Prescribers - Adult Practice
N (%)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 30 days?
Number Eligible 879
Eligible But No Response 26
Total Number of  Responses 853
 0% 213 (25.0)
 1-10% 242 (28.4)
 11-20% 94 (11.0)
 21-30% 55 (6.4)
 31-40% 37 (4.3)
 41-50% 23 (2.7)
 51-60% 43 (5.0)
 61-70% 25 (2.9)
 71-80% 23 (2.7)
 81-90% 23 (2.7)
 91-100% 75 (8.8)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 12 months?
Number Eligible 879
Eligible But No Response 20
Total Number of  Responses 859
 0% 70 (8.1)
 1-10% 284 (33.1)
 11-20% 99 (11.5)
 21-30% 74 (8.6)
 31-40% 47 (5.5)
 41-50% 41 (4.8)
 51-60% 33 (3.8)
 61-70% 27 (3.1)
 71-80% 35 (4.1)
 81-90% 37 (4.3)
 91-100% 112 (13.0)
19
Table 6b. Use of  INSPECT by Controlled Substance Prescribers - Pediatric Practice
N (%)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 30 days?
Number Eligible 74
Eligible But No Response 1
Total Number of  Responses 73
 0% 33 (45.2)
 1-10% 27 (37.0)
 11-20% 1 (1.4)
 21-30% 2 (2.7)
 31-40% 2 (2.7)
 41-50% 0 (0.0)
 51-60% 2 (2.7)
 61-70% 0 (0.0)
 71-80% 1 (1.4)
 81-90% 1 (1.4)
 91-100% 4 (5.5)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 12 months?
Number Eligible 74
Eligible But No Response 1
Total Number of  Responses 73
 0% 19 (26.0)
 1-10% 32 (43.8)
 11-20% 6 (8.2)
 21-30% 5 (6.8)
 31-40% 3 (4.1)
 41-50% 1 (1.4)
 51-60% 2 (2.7)
 61-70% 1 (1.4)
 71-80% 1 (1.4)
 81-90% 2 (2.7)
 91-100% 1 (1.4)
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Table 6c. Use of  INSPECT by Controlled Substance Prescribers - Both Adult and Pediatric Practice
N (%)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 30 days?
Number Eligible 1267
Eligible But No Response 28
Total Number of  Responses 1239
 0% 187 (15.1)
 1-10% 342 (27.6)
 11-20% 158 (12.8)
 21-30% 114 (9.2)
 31-40% 64 (5.2)
 41-50% 48 (3.9)
 51-60% 58 (4.7)
 61-70% 35 (2.8)
 71-80% 55 (4.4)
 81-90% 54 (4.4)
 91-100% 124 (10.0)
For what percent of  patients to whom you have prescribed controlled substances did you review INSPECT 
information in the past 12 months?
Number Eligible 1267
Eligible But No Response 24
Total Number of  Responses 1243
 0% 62 (5.0)
 1-10% 365 (29.4)
 11-20% 173 (13.9)
 21-30% 101 (8.1)
 31-40% 65 (5.2)
 41-50% 44 (3.5)
 51-60% 66 (5.3)
 61-70% 36 (2.9)
 71-80% 88 (7.1)
 81-90% 75 (6.0)
 91-100% 168 (13.5)
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Table 6d.  Use of  Inspect by Controlled Substance Prescribers
N (%)
Consider the patients for whom you have reviewed INSPECT in the past 12 month period.  For what percent of  these 
cases did the information you obtained from INSPECT alter your prescribing decision?
Number Eligible 2,288
Eligible But No Response 66
Total Number of  Responses 2,222
 0% 372 (16.7)
 1-10% 661 (29.7)
 11-20% 261 (11.7)
 21-30% 223 (10.0)
 31-40% 120 (5.4)
 41-50% 177 (8.0)
 51-60% 131 (5.9)
 61-70% 38 (1.7)
 71-80% 84 (3.8)
 81-90% 44 (2.0)
 91-100% 111 (5.0)
The last time you considered writing a prescription for a controlled substance, did you consult INSPECT?
Number Eligible 2,288
Eligible But No Response 30
Total Number of  Responses 2,258
 Yes 836 (37.0)
 No 1,422 (63.0)
Did the information you learned from INSPECT prompt you to change your treatment plan?
Number Eligible 836
Eligible But No Response 7
Total Number of  Responses 829
 Yes 415 (50.1)
 No 414 (49.9)
Usefulness of  INSPECT
The survey asked all participants who had heard 
of  INSPECT (n = 4,981) to indicate whether 
they believed INSPECT was or was not useful for 
achieving four specific goals.  Most respondents 
believed that INSPECT was useful for monitoring 
prescription histories with regard to controlled 
substances (93.9%), for decreasing “doctor shopping” 
(80.7%), for decreasing the incidence of  controlled 
prescription drug misuse (79.9%), and for decreasing 
the incidence of  controlled prescription drug 
diversion (62.6%; see Table 7).
Table 7.  Usefulness of  INSPECT 
Do you think INSPECT is a useful program for… N (%)
Number Eligible 4,981
Eligible But No Response 157
Total Number of  Responses 4,824
…monitoring prescription histories with regard to controlled substances? 4,529 (93.9)
…decreasing the incidence of  ‘doctor shopping’? 3,891 (80.7)
…decreasing the incidence of  controlled prescription drug misuse? 3,856 (79.9)
…decreasing the incidence of  controlled prescription drug diversion? 3,021 (62.6)
…other reasons 156 (3.2)
Barriers to Using INSPECT
The survey asked the 1,430 respondents who stated 
they knew about INSPECT but did not use it to 
indicate their primary reason for not using it.  The 
top two specific reasons endorsed by respondents 
for not using INSPECT were because they did not 
think they could (21.2%) or because their practice 
only involved seeing inpatients (15.8%).  Most 
participants who did not use INSPECT (52.2%) 
indicated they did not use it for a reason other than 
the ones listed (see Table 8). 
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Table 8.  Primary Reason for not Using INSPECT
N (%)
Number Eligible 1,430
Eligible But No Response 54
Total Number of  Responses 1,376
I did not think I could use it. 292 (21.2)
Because of  my license type. 37 (2.7)
Because I only see inpatients. 217 (15.8)
Because I am not convinced it is helpful. 112 (8.1)
Because of  some other reason. 718 (52.2)
Breakdown of  Other Reasons
Number Eligible 718
Eligible But No Response 3
Total Number of  Responses 715
No need to check INSPECT/not relevant for practice 195 (27.3)
Respondent does not prescribe controlled substances 117 (16.4)
Difficulties signing up or registering for INSPECT 115 (16.1)
Respondent has out-of-state practice 90 (12.6)
INSPECT is too hard to use or not helpful 82 (11.5)
Don’t know how to use INSPECT 47 (6.6)
Retired/Not currently practicing 31 (4.3)
INSPECT is checked by someone else in office 23 (3.2)
No access to INSPECT on site/Use not encouraged by employer 15 (2.1)
The survey asked all participants who had heard 
of  INSPECT (n = 4,981), regardless of  whether or 
not they had used it, to indicate if  they had or had 
not encountered specific barriers preventing  them 
from using INSPECT.  Having insufficient time 
was the most frequently cited barrier respondents 
experienced for using INSPECT.  Table 9 describes 
the percentage of  participants who experienced 
various barriers related to using INSPECT. 
Table 9.  Barriers for Using INSPECT
N (%)
Number Eligible 4,981
Eligible But No Response 138
Total Number of  Responses 4,843
There are no barriers to using INSPECT in my practice 1,878 (38.8)
Insufficient time 2,049 (42.3)
Lack of  reimbursement for additional time to use the system 495 (10.2)
Lack of  access to computer/internet 240 (5.0)
Currently not registered to use INSPECT 915 (18.9)
Afraid of  legal ramifications 107 (2.2)
Other reason 581 (12.0)
Administration and Impact of  INSPECT
The survey asked all respondents that had heard of  
INSPECT (n = 4,981) to describe their opinions 
on four issues related to the administration of  
the INSPECT database and its data.  First, survey 
participants were asked to indicate whether they 
thought INSPECT should be linked to a national 
controlled medication database.  The majority of  
participants who knew about INSPECT (90.7%) 
said that it should be.  
Second, the survey asked participants whether 
they believed medical professionals ought to be 
required to access INSPECT prior to writing a 
prescription for a controlled medication.  Most 
respondents familiar with INSPECT (66.8%) were 
against such a requirement (see Table 10).  Table XX 
provides a comparison of  survey participants who 
were for and against requiring medical professionals 
to check INSPECT prior to writing a prescription 
for a controlled medication.  Supporters of  a 
requirement to check INSPECT prior to writing a 
controlled medication prescription were more likely 
to be pharmacists (54.4%), to be female (56.2%),  
to be younger (22.1% were 35 years or less), and to 
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have been practicing for fewer years (24.3% were 
practicing for 5 years or less).  Respondents who did 
not support a requirement to check INSPECT prior 
to writing a controlled medication prescription were 
more likely to be MDs (39.4%) or dentists (15.8%), 
were more likely to be male (54.3%), and were more 
likely to be older (35.7% were 56 years or older). 
Third, the survey had participants indicate if  
they believed criminal justice professionals such 
as the police or DEA should be allowed access to 
INSPECT data.  In considering access to INSPECT 
for patient-related information, most participants 
(57.3%) stated that criminal justice professionals 
should have access to this data, but only under 
certain circumstances such as identifying potential 
drug diversion for illicit purposes or during the 
investigation of  an ongoing case involving controlled 
substances. In regards to criminal justice professionals 
accessing INSPECT to determine whether providers 
are potentially overprescribing controlled substances, 
the largest percentage of  respondents (49.6%) 
believed access should only be given under certain 
circumstances such as when trying to identify 
potential “pill mills” or during the investigation of  
an ongoing case involving controlled substances (see 
Table 10).
Table 10. INSPECT Administration and Access
N (%)
Should INSPECT be linked to a national controlled medication database?
Number Eligible 4,981
Eligible But No Response 143
Total Number of  Responses 4,838
Yes 4,386 (90.7)
No 452 (9.3)
Should medical professionals be required to access INSPECT prior to writing a prescription for a controlled 
medication?
Number Eligible 4,981
Eligible But No Response 90
Total Number of  Responses 4,891
Yes 1,581 (32.3)
No 3,310 (67.7)
Should criminal justice professionals (e.g., police, the DEA) be allowed to access INSPECT for patient information?
Number Eligible 4,981
Eligible But No Response 121
Total Number of  Responses 4,860
No 708 (14.6)
Yes 1,376 (28.3)
Yes, but only under certain circumstances 2,776 (57.1)
Number Eligible 2,776
Eligible But No Response 37
Total Number of Responses 2,739
To identify potential drug diversion for illicit purposes 1,580 (57.7)
During the investigation of  an ongoing case involving controlled substances 2,540 (92.7)
Under other certain circumstances 131 (4.8)
Should criminal justice professionals (e.g., police, the DEA) be allowed to access INSPECT to determine if  medical 
providers are potentially overprescribing controlled prescription medication?
Number Eligible 4,981
Eligible But No Response 90
Total Number of  Responses 4,891
No 775 (15.8)
Yes 1,691 (34.6)
Yes, but only under certain circumstances 2,425 (49.6)
Number Eligible 2,425
Eligible But No Response 36
Total Number of  Responses 2,389
To identify potential “pill mills” 1,465 (61.3)
During the investigation of  an ongoing case involving controlled substances. 2,131 (89.2)
Under other certain circumstances 127 (5.3)
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Table 10a. Characteristics of  Survey Participants Who Believe Medical Professionals Should and Should Not Be Required 
to Check INSPECT Prior to Writing a Prescription for a Controlled Substance Medication
Should be required to 
check INSPECT
Should not be required to 
check INSPECT
N (%) N (%) z p
License Type
 Medical Doctor 319 (20.2) 1305 (39.4) 14.5 <.001
 Doctor of  Osteopathy 29 (1.8) 119 (3.6) 3.9 <.001
 Doctor of  Podiatric Medicine 5 (0.3) 30 (0.9) 2.8 0.005
 Physician Assistant 26 (1.6) 138 (4.2) 5.5 <.001
 Nurse Practitioner 254 (16.1) 544 (16.4) 0.3 0.790
 Dentist 67 (4.2) 523 (15.8) 14.3 <.001
 Pharmacist 860 (54.4) 586 (17.7) 25.9 <.001
 Other 5 (0.3) 28 (0.8) 2.4 0.016
 Not provided 16 (1.0) 37 (1.1)
Practice Type
 Adult 320 (20.2) 1033 (31.2) 8.5 <.001
 Pediatric 33 (2.1) 179 (5.4) 6.2 <.001
 Both 328 (20.7) 1397 (42.2) 16.1 <.001
 Not applicable – Pharmacists 860 (54.4) 586 (17.7) .259 <.001
 Not provided 40 (2.5) 115 (3.5)
Gender
 Male 656 (41.5) 1798 (54.3) 8.5 <.001
 Female 888 (56.2) 1430 (43.2) 8.6 <.001
 Not provided 37 (2.3) 82 (2.5)
Race
 Asian 95 (6.0) 108 (3.3) 4.0 <.001
 African-American 44 (2.8) 58 (1.8) 2.1 0.035
 Caucasian 1334 (84.4) 2916 (88.1) 3.5 .001
 Latino 22 (1.4) 28 (0.8) 1.8 0.072
 Other Race 44 (2.8) 97 (2.9) 0.2 0.844
 Not provided 42 (2.7) 103 (3.1)
Age
 <35 years 349 (22.1) 482 (14.6) 6.2 <.001
 36-45 342 (21.6) 693 (20.9) 0.6 0.577
 45-55 372 (23.5) 837 (25.3) 1.4 0.169
 56 and older 469 (29.7) 1183 (35.7) 4.2 <.001
 Not provided 49 (3.1) 115 (3.5)
Years in Practice
 5 years or less 384 (24.3) 638 (19.3) 3.9 <.001
 6-10 years 215 (13.6) 456 (13.8) 0.2 0.849
 11-19 years 296 (18.7) 687 (20.8) 1.7 0.082
 20-29 years 314 (19.9) 718 (21.7) 1.5 0.145
 30-39 years 228 (14.4) 567 (17.1) 2.5 0.014
 40 years or more 98 (6.4) 191 (5.8) 4.1 <.001
 Not provided 46 (2.9) 53 (1.6)
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Impact of  INSPECT on Prescribing and 
Dispensing Behavior
To determine what impact INSPECT may be having 
on prescribing behavior, the 3,148 participants 
who had both heard of  INSPECT and who 
had prescribed controlled substances in the past 
12 months were asked if  they believed that law 
enforcement and regulatory agencies had used 
INSPECT to monitor their prescribing behavior 
more closely.  Only a minority of  participants (36.4%) 
believed their prescribing behaviors were being 
monitored more closely.  Respondents who believed 
they were being monitored were further asked if  they 
had changed their prescribing practices in light of  this 
increased monitoring.  A small percentage of  these 
participants (17.5%) said that they had changed their 
prescribing practices and were now prescribing fewer 
or far fewer controlled substances (see Table 11).
Table 11.  Impact of  INSPECT on Prescribing Behavior 
N (%)
In the past twelve month period do you believe that law enforcement and regulatory agencies have used INSPECT to 
monitor your prescribing behavior more closely? 
Number Eligible 3,148
Eligible But No Response 78
Total Number of  Responses 3,070
Yes 1,117 (36.4)
No 1,953 (63.6)
Has this caused you to change your prescribing practices regarding controlled medication?
Number Eligible 1,117
Eligible But No Response 11
Total Number of  Responses 1,106
Yes 194 (17.5)
No 912 (82.5)
How have your prescribing practices changed due to your perception of  greater oversight?
Number Eligible 194
Eligible But No Response 8
Total Number of  Responses 186
I prescribe FAR FEWER controlled substances 60 (32.3)
I prescribe FEWER controlled substances 122 (65.6)
I prescribe MORE controlled substances 4 (2.2)
The survey asked the 1,910 participants who 
dispensed controlled substances in the past 12 
months and who had heard of  INSPECT a parallel 
set of  questions regarding monitoring of  their 
dispensing behavior.  Just over 30 percent (32.9%) 
of  dispensers believed that law enforcement and 
regulatory agencies had been using INSPECT to 
monitor their dispensing behavior more closely.  Of  
dispensers who believed they were being monitored 
(n = 613), most (70.2%) had not changed their 
dispensing practices.  Dispensers that had changed 
their dispensing practices due to their perception 
of  greater oversight (29.8%) said they were now 
dispensing fewer or far fewer controlled substances 
(see Table 12).
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Table 12. Impact of  INSPECT on Dispensing Behavior 
N (%)
In the past 12 month period do you believe that law enforcement and regulatory agencies have used INSPECT to 
monitor your dispensing behavior more closely?
Number Eligible 1,910
Eligible But No Response 45
Total Number of  Responses 1,865
Yes 613 (32.9)
No 1,252 (67.1)
Has this caused you to change your dispensing practices regarding controlled medications?
Number Eligible 613
Eligible But No Response 9
Total Number of  Responses 604
Yes 180 (29.8)
No 424 (70.2)
How have your dispensing practices changed due to your perception of  greater oversight?
Number Eligible 180
Eligible But No Response 2
Total Number of  Responses 178
I dispense FAR FEWER controlled substances 23 (12.9)
I dispense FEWER controlled substances 143 (80.3)
I dispense MORE controlled substances 12 (6.7)
Other Changes in Prescribing and Dispensing 
Behavior
To explore whether any general trends existed in 
prescribing and dispensing of  controlled substances, 
all survey participants who reported prescribing 
(n = 3,783) or dispensing controlled substances 
(n = 2,145) in the past year were asked whether 
their prescribing or dispensing practices related to 
controlled substances had changed in the past 12 
months.  Of  the prescribers in the sample, most 
(64.3%) stated that they had not made any changes 
in their prescribing practices related to controlled 
substances in the past 12 months.  Prescribers 
that reported making changes indicated that they 
were now prescribing fewer or far fewer controlled 
substances.  The factors most commonly cited 
by prescribers for the change in their prescribing 
practices were an increased professional awareness 
of  risks, benefits, and other solutions and INSPECT 
providing greater access to patient prescription drug 
histories (see Table 13).  
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Table 13.  Changes in Prescribing Practices in the Past 12 Months.
N (%)
In the past 12 month period have you changed your prescribing practices related to controlled substances?
Number Eligible 3,783
Eligible But No Response 72
Total Number of  Responses 3,711
 Yes 1,325 (35.7)
 No 2,386 (64.3)
How have your prescribing practices changed?
Number Eligible 1,325
Eligible But No Response 32
Total Number of  Responses 1,293
 I prescribe FAR FEWER controlled substances 317 (24.5)
 I prescribe FEWER controlled substances 867 (67.1)
 I prescribe MORE controlled substances 96 (7.4)
 I prescribe FAR MORE controlled substances 13 (1.0)
What factors led you to change your prescribing practices?
Number Eligible 1,325
Eligible But No Response 27
Total Number of  Responses 1,298
 Change in patient mix 345 (26.6)
 New professional practice standards and protocols 556 (42.8)
 Increased professional awareness of  risks, benefits, and other solutions 905 (69.7)
 Increased state or federal guidelines and recommendations 462 (35.6)
 Increased law enforcement activity. 135 (10.4)
 INSPECT providing greater access to patient prescription drug history 735 (56.6)
 Increased patient awareness of  risks and benefits 204 (15.7)
 I am afraid of  legal ramifications 203 (15.6)
 Increased referrals from other physicians/providers for treatment of  acute (surgical/
traumatic/short-term) pain patients
66 (5.1)
 Increased referrals from other physicians/providers for treatment of  chronic pain patients 122 (9.4)
 Other reason for change 134 (10.3)
Regarding the individuals who reported dispensing 
controlled substances in the past 12 months, 
just over one third (35.2%) admitted to making 
changes to their dispensing practices.  Dispensers 
who made a change in their dispensing practices 
primarily said they were now dispensing fewer 
controlled substances (69.3%).  Dispensers said the 
main reasons for making changes in their dispensing 
practices were due to an increased professional 
awareness of  risks, benefits, and other solutions; 
INSPECT providing greater access to patient 
prescription drug histories; and new professional 
practice standards and protocols (see Table 14).
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Table 14.  Changes in Dispensing Practices in the Past 12 months.
N (%)
In the past 12 month period, have you changed your dispensing practices related to controlled substances?
Number Eligible 2,145
Eligible But No Response 45
Total Number of  Responses 2,100
 Yes 739 (35.2)
 No 1,361 (64.8)
How have your dispensing practices changed?
Number Eligible 739
Eligible But No Response 22
Total Number of  Responses 717
 I dispense FAR FEWER controlled substances 101 (14.1)
 I dispense FEWER controlled substances 497 (69.3)
 I dispense MORE controlled substances 101 (14.1)
 I dispense FAR MORE controlled substances 18 (2.5)
What factors led you to change your dispensing practices?
Number Eligible 739
Eligible But No Response 20
Total Number of  Responses 719
 Change in my patient mix 189 (26.3)
 New professional practice standards and protocols 368 (51.2)
 Increased awareness of  risks, benefits, and other solutions 383 (53.3)
 Increased state or federal guidelines and recommendations 274 (38.1)
 Increased law enforcement activity 99 (13.8)
 INSPECT providing greater access to patient prescription drug history 375 (52.2)
 Increased patient awareness of  risks and benefits 73 (10.2)
 I am afraid of  legal ramifications 135 (18.8)
 Increased referrals from other physicians/providers for treatment of  acute 
(surgical/traumatic/short-term) pain patients
52 (7.2)
 Increased referrals from other physicians/providers for treatment of  chronic 
pain patients.
86 (12.0)
 Other reason 95 (13.2)
General Views of  Prescription Drug Abuse
To gauge participants’ perceptions of  the abuse of  
controlled prescription medication, the survey had 
all respondents (N = 5,994) report how concerned 
they were about controlled prescription drug abuse 
among the patients in their practice and then how 
concerned they were about controlled prescription 
drug abuse in their community.  In terms of  their 
practice, over half  of  all survey respondents (57.4%) 
were at least moderately concerned about controlled 
prescription drug abuse among their patients.  
Respondents appeared much more concerned 
about controlled prescription drug abuse within the 
community with 85.7% reporting at least moderate 
concern (see Table 12).  The survey next asked 
respondents to indicate what percent of  their patients 
who take controlled prescription medications they 
felt misused or abused these medications.  The largest 
percentage of  respondents (44.4%) believed that one 
to 10.0% of  their patients were misusing or abusing 
their controlled prescription medication.  When the 
survey had participants indicate what percent of  
patients in Indiana taking controlled prescription 
medications were misusing or abusing their 
medication, most participants believed the percentage 
was somewhere between 11.0% to 20.0% (23.6%) or 
21.0% to 30.0%  (22.2%) of  patients (see Table 15).  
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Table 15.  Concerns about and Estimates of  Controlled Prescription Medication Misuse or Abuse
N (%)
How concerned are you about prescription drug abuse among the patients in your practice?
Number Eligible 5,994
Eligible But No Response 195
Total Number of  Responses 5,799
Extremely concerned 1,436 (24.8)
Moderately concerned 1,893 (32.6)
Slightly concerned 1,726 (29.8)
Not concerned at all 744 (12.8)
How concerned are you about prescription drug abuse in your community?
Number Eligible 5,994
Eligible But No Response 180
Total Number of  Responses 5,814
Extremely concerned 2,668 (45.9)
Moderately concerned 2,315 (39.8)
Slightly concerned 736 (12.7)
Not concerned at all 95 (1.6)
What percent of  your patients who are taking controlled prescription medications do you feel misuse/
abuse the medications?
Number Eligible 5,994
Eligible But No Response 239
Total Number of  Responses 5,755
0% 552 (9.6)
1-10% 2,553 (44.4)
11-20% 951 (16.5)
21-30% 672 (11.7)
31-40% 325 (5.6)
41-50% 276 (4.8)
51-60% 230 (4.0)
61-70% 0 (0.0)
71-80% 132 (2.3)
81-90% 46 (0.8)
91-100% 18 (0.3)
What percent of  patients in Indiana taking controlled prescription medications do you feel misuse/
abuse the medication?
Number Eligible 5,994
Eligible But No Response 311
Total Number of  Responses 5,683
0% 81 (1.4)
1-10% 1,008 (17.7)
11-20% 1,339 (23.6)
21-30% 1,264 (22.2)
31-40% 658 (11.6)
41-50% 510 (9.0)
51-60% 383 (6.7)
61-70% 188 (3.3)
71-80% 178 (3.1)
81-90% 54 (1.0)
91-100% 20 (0.4)
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Use of  Controlled Substances
To determine how widely used participants thought 
controlled prescription medications were, the 
survey asked participants to estimate the percent 
of  their patients who they believed were currently 
prescribed opioids, stimulants, CNS depressants, 
or opioids combined with benzodiazepines. 
Most participants did not believe that opioids, 
stimulants, CNS depressants, or opioids combined 
with benzodiazepines were commonly prescribed to 
their patients. The largest percentage of  participants 
estimated that one to 10.0% of  their patients were 
currently prescribed opioids (32.1%), stimulants 
(44.4%), CNS depressants (32.0%), or opioids with 
benzodiazepines (33.1%, see Table 16).
Table 16.  Percent of  Patients Prescribed Controlled Substances
N (%)
What percentage of  your patients do you estimate are currently prescribed opioids (pain relievers)?
Number Eligible 5,994
Eligible But No Response 484
Total Number of  Responses 5,510
0% 467 (8.5)
1-10% 1,769 (32.1)
11-20% 918 (16.7)
21-30% 777 (14.1)
31-40% 438 (7.9)
41-50% 307 (5.6)
51-60% 214 (3.9)
61-70% 213 (3.9)
71-80% 147 (3.2)
81-90% 142 (2.6)
91-100% 91 (1.7)
What percentage of  your patients do you estimate are currently prescribed stimulants?
Number Eligible 5,994
Eligible But No Response 693
Total Number of  Responses 5,301
0% 1,448 (28.1)
1-10% 2,355 (44.4)
11-20% 711 (13.4)
21-30% 398 (7.5)
31-40% 166 (3.1)
41-50% 86 (1.6)
51-60% 43 (0.8)
61-70% 24 (0.5)
71-80% 16 (0.3)
81-90% 10 (0.2)
91-100% 4 (0.1)
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Table 16 Cont.  Percent of  Patients Prescribed Controlled Substances
N (%)
What percentage of  your patients do you estimate are currently prescribed CNS depressants?
Number Eligible 5,994
Eligible But No Response 664
Total Number of  Responses 5,330
0% 969 (18.2)
1-10% 1,705 (32.0)
11-20% 911 (17.1)
21-30% 664 (12.5)
31-40% 380 (7.1)
41-50% 261 (4.9)
51-60% 173 (3.2)
61-70% 133 (2.5)
71-80% 82 (1.5)
81-90% 40 (0.8)
91-100% 12 (0.2)
How often are opioids and benzodiazepines prescribed simultaneously for your patients?
Number Eligible 5,994
Eligible But No Response 415
Total Number of  Responses 5,579
0% 1,610 (28.9)
1-10% 1,848 (33.1)
11-20% 631 (11.3)
21-30% 443 (7.9)
31-40% 289 (5.2)
41-50% 232 (4.2)
51-60% 190 (3.4)
61-70% 128 (2.3)
71-80% 126 (2.3)
81-90% 54 (1.0)
91-100% 28 (0.5)
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Management of  Patients with Chronic Non-
Terminal Pain
The next section of  the survey had participants 
report on their treatment of  patients with 
chronic non-terminal pain.  The survey asked all 
participants, except for Pharmacists (n = 4,306), to 
indicate what percentage of  their patients they see 
for chronic, non-terminal pain.  Of  participants 
who provided an estimate, the largest percentage 
(41.4%) said they saw no patients for treatment of  
chronic, non-terminal pain.  Survey participants 
who reported seeing any patients for chronic, non-
terminal pain (n = 2,437) were asked to indicate 
how they typically managed these patients.  Most 
respondent (53.8%) said they managed chronic, 
non-terminal pain patients within their practice in 
consultation with other professionals as needed.  
The remaining respondents managed patients with 
chronic non-terminal pain on their own (11.4%) 
or referred these patients to other practitioners 
(34.8%).  
Survey participants that managed patients with 
chronic, non-terminal pain within their practice (n 
= 1,545) were asked a series of  follow-up questions 
regarding their treatment approach.  When asked how 
often they used validated mental health screening 
tools, such as the Patient Health Questionnaire, to 
screen their chronic, non-terminal pain patients 
for mental health issues before prescribing opioids, 
most respondents said they rarely (26.8%) or never 
(35.9%) did so.  Similarly most participants rarely 
(27.0%) or never (49.3%) used validated addiction 
screening tools, such as the Opioid Risk Tool, to 
screen their chronic, non-terminal pain patients 
for potential addiction issues.  Survey participants 
were also not very likely to use urine or other drug 
screening to monitor their chronic, non-terminal pain 
patients on opioids with only 30.0% reporting that 
they always (12.7%) or usually (17.3%) did so.  Lastly, 
respondents who managed patients with chronic, 
non-terminal pain in their practice were asked to 
indicate how they monitored their patients’ response 
to pain medications.  Most respondents said that they 
used their patients’ self-reports of  pain alleviation 
(85.0%), used their patients’ self-reports of  physical 
and psychosocial functioning (73.3%), or used their 
personal observations of  their patients’ physical 
functioning (74.7%; see Table 17).
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Table 17.  Treatment of  Patients with Chronic, Non-Terminal Pain
N (%)
What percentage of  your patients do you see for chronic, non-terminal pain?
Number Eligible 4,306
Eligible But No Response 145
Total Number of  Responses 4,161
0% 1,724 (41.4)
1-10% 1,302 (31.3)
11-20% 421 (10.1)
21-30% 238 (5.7)
31-40% 155 (3.7)
41-50% 84 (2.0)
51-60% 56 (1.3)
61-70% 52 (1.2)
71-80% 47 (1.1)
81-90% 40 (1.0)
91-100% 42 (1.0)
How do you typically manage your patients with chronic, non-terminal pain?
Number Eligible 2,437
Eligible But No Response 67
Total Number of  Responses 2,370
I am comfortable managing these patients within my practice. 271 (11.4)
I manage these patients within my practice in consultation with other professionals as 
needed.
1,274 (53.8)
I refer all patients with chronic pain medication needs. 825 (34.8)
How often do you use validated mental health screening tools to screen your chronic, non-
terminal pain patients for mental health issues before prescribing opioids?
Number Eligible 1,545
Eligible But No Response 26
Total Number of  Responses 1,519
 Always 102 (6.7)
 Usually 192 (12.6)
 Occasionally 272 (17.9)
 Rarely 407 (26.8)
 Never 546 (35.9)
How often do you use validated addiction screening tools to screen your chronic, 
non-terminal pain patients for potential addiction issues?
Number Eligible 1,545
Eligible But No Response 27
Total Number of  Responses 1,518
 Always 66 (4.3)
 Usually 101 (6.7)
 Occasionally 193 (12.7)
 Rarely 410 (27.0)
 Never 748 (49.3)
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Table 17 Cont. Treatment of  Patients with Chronic, Non-Terminal Pain
N (%)
How often do you use urine or other drug screening to monitor your chronic, non-
terminal pain patients on opioids?
Number Eligible 1,545
Eligible But No Response 44
Total Number of  Responses 1,501
 Always 190 (12.7)
 Usually 259 (17.3)
 Occasionally 354 (23.6)
 Rarely 288 (19.2)
 Never 410 (27.3)
How do you monitor patient response to pain medications?
Number Eligible 1,545
Eligible But No Response 33
Total Number of  Responses 1,512
Patient self-report of  pain alleviation 1,285 (85.0)
Patient self-report of  physical and psychosocial function 1,108 (73.3)
Observation of  physical function 1,130 (74.7)
Other 121 (8.0)
Risks and Benefits of  Opioid Treatment for 
Chronic Non-Terminal Pain
The final three questions on the survey asked all 
respondents (N = 5,994) to rank their level of  
knowledge of  the medical risks of  opioid treatment 
for chronic non-terminal pain patients, rank their 
level of  knowledge of  the benefits of  opioid 
treatment for chronic non-terminal pain patients, 
and rank their level of  knowledge of  the risks and 
benefits of  prescribing opioids and benzodiazepines 
together.  Most respondents ranked their level of  
knowledge about the benefits of  opioid treatment to 
be moderately high (42.9%).  Similarly, most survey 
participants rated their knowledge about the risks of  
opioid treatment to also be moderately high (40.8%).  
In terms of  the risks and benefits of  prescribing 
opioids and benzodiazepines together, the largest 
percentage of  survey respondents (37.8%)also viewed 
their knowledge as moderately high (see table 18).
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Table 18.  Knowledge of  Risks and Benefits of  Opioid Treatment
N %
Rank your level of  knowledge of  the medical risks of  opioid treatment for chronic non-terminal pain patients
Number Eligible 5,994
Eligible But No Response 209
Total Number of  Responses 5,785
1 – Low 142 (2.5)
2 139 (2.4)
3 236 (4.1)
4 211 (3.6)
5 657 (11.4)
6 555 (9.6)
7 1,102 (19.0)
8 1,382 (23.9)
9 752 (13.0)
10 – High 609 (10.5)
Rank your level of  knowledge of  the medical benefits of  opioid treatment for chronic non-terminal pain patients.
Number Eligible 5,994
Eligible But No Response 186
Total Number of  Responses 5,808
1 – Low 165 (2.8)
2 165 (2.8)
3 290 (5.0)
4 275 (4.7)
5 759 (13.1)
6 601 (10.3)
7 1,106 (19.0)
8 1,268 (21.8)
9 658 (11.3)
10 – High 521 (9.0)
Rank your level of  knowledge of  the medical risks/benefits of  prescribing opioids and benzodiazepines together.
Number Eligible 5,994
Eligible But No Response 244
Total Number of  Responses 5,750
1 – Low 207 (3.6)
2 165 (2.9)
3 279 (4.9)
4 246 (4.3)
5 662 (11.5)
6 505 (8.8)
7 927 (16.1)
8 1,250 (21.7)
9 771 (13.4)
10 – High 738 (12.8)
36
Two open-ended questions sought input from 
respondents on patients’ and the community’s 
educational needs and their thoughts about the 
issues covered in the survey.  Over one thousand 
survey participants submitted comments (n = 1,725) 
resulting in 3,891 statements covering education, 
policy, monitoring, and practice.  Table 19 provides 
a breakdown of  the coding for the 3,891 statements. 
Overall, the emergent themes centered on content 
or target audience. Each of  the four broad themes 
was distinguished by sub-themes coalescing around 
the content or the target population indicated. The 
following sections briefly summarize the responses 
to the open-ended questions.  Sample quotations 
and frequency values by theme as well as subthemes 
are included to provide a deeper  perspective on the 
range of  comments offered.
Table 19.  Coding scheme for open-ended questions
Theme N (%)
Education 
 General Education Comments 187 (4.8)
 Patients 391 (10.0)
 Providers 97 (2.5)
  Clinical best practice/s 230 (5.9)
  Law enforcement/regulations 93 (2.4)
  National/State/Local data 39 (1.0)
  Research 67 (1.7)
 Community 118 (3.0)
Policy
 General policy comments 6 (0.2)
 General health 97 (2.5)
 Drug 115 (3.0)
 Institutional 9 (0.2)
  Government 95 (2.4)
   Expand 131 (3.4)
   Constrict 92 (2.4)
  Hospital/practice settings 134 (3.4)
 Patient accountability 92 (2.4)
Monitoring
 General monitoring comments 209 (5.4)
 Improve INSPECT 319 (8.2)
 Linkages 91 (2.3)
 Monitoring of  providers 96 (2.5)
Practice
 General practice comments 635 (16.3)
 Screening and evaluation 178 (4.6)
 Interventions 208 (5.3)
  Alternative 58 (1.5)
 Improve communication 104 (2.7)
OPEN-ENDED 
QUESTION 
RESPONSE 
SUMMARIES
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Education
Education comments (n = 1,222) included 
suggestions for information targeting patients (n 
= 391), providers (n = 526), and the community 
(n = 118). A number of  responses indicated that 
survey participants either provide or would provide 
materials to their patients. Participants asked that 
these materials be easily understood by the general 
population and written at an elementary reading 
level. Responses regarding patient education and 
community education made up the majority of  
comments across all themes. Regarding patient 
education, one participant wrote: 
“Maybe when we Rx opioids, we should 
require handouts about opioid risks, benefits, 
and the average time before a typical pt 
[patient] may become addicted. Pts don’t 
realize addiction can happen to anyone. They 
also don’t seem to hear enough about non-
addictive side effects: constipation, etc. Also, 
many pts seem to drive vehicles on opioids 
and then they’re surprised when they get in 
an accident. They don’t seem to realize their 
reaction time is slowed.”
On the pharmacy end, “Let it be known that all 
pharmacies will not fill any controlled Rx no sooner 
than 3 days before next fill is due and publicize to 
patients and Drs. that this is a standard of  practice.” 
Survey respondents would also like to see education 
targeting the community. For example, one 
participant stated:
 “More awareness in the community on 
the dangers of  drug addiction, opioid and 
benzodiazepine abuse. Increased education 
should be mandated to general practitioners in 
the use of  these medications, as the epidemic 
is starting at that level - little education in 
residency is given to general practitioners, yet 
they are the forefront of  addiction medicine.”
Only a rare few participants felt additional 
education would have no impact as most comments 
encouraged monitoring and public health agencies 
to distribute patient and community-level education 
materials and campaigns.
As addressed in the previous comment, a number 
of  participants suggested educational forums 
targeting medical providers (n = 526 ), especially 
specific to best prescribing practices (n = 230 ), 
current regulations and law enforcement efforts (n 
= 93), national/state/local statistics on prescription 
drug abuse (n = 39), as well as further research on 
appropriate treatment modalities and improved 
prescribing practice (n = 67). One participant spoke 
about these needs in the following,
“Education regarding best-practice policies 
and procedures for prescribing and monitoring 
controlled substances. Education regarding 
better prescreening for patients for whom 
you are considering prescribing controlled 
substances. Better education about ways 
to counsel patients about risks of  chronic 
controlled substances.”
In support of  recent efforts one participant 
stated, “The DEA presentation/CE seminar last 
December was excellent. I think we should have 
more of  those. It was free, it was applicable, and I 
got CE [continuing education].” Speaking to data 
needs, a participant wrote, “If  INSPECT data is 
being analyzed for trends, percentages, etc., I would 
like to hear about that data.” And finally, regarding 
further research, “[I’m] interested in knowing what 
the risk/benefits of  ADHD medication use is in 
adults. What is the best regimen for chronic pain?” In 
total, comments request further educational materials 
for patients, campaigns targeting the community, 
and continuing education opportunities that cover 
prescribing practices, regulations/law enforcement, 
data, and further research.
Policy
Policy comments (n= 771) discussed general 
health (n = 97), drug (n = 115), institutional (n = 
461), which was broken down into government 
policy (n = 318) and practice site/professional 
organizations (n = 134), and patient accountability 
(n = 92). Government policy requests were further 
broken down into whether the comment suggested 
constricting government action (n = 131) or 
expanding it (n = 92). A significant number of  
policy comments regarding general health involved 
insurance coverage issues, e.g. insurance not covering 
pain management. Indeed, a number of  comments 
requested Medicaid coverage of  pain management 
and the time to manage the best treatment plan. 
Regarding drug policy, one provider stated, 
“There needs to be a consistent policy that 
is on the state and federal level about how to 
deal with chronic pain. The fed and JC [Joint 
Commission] want us to inquire about “level of  
pain”, “rate your pain level”, etc. and then they 
expect us to treat this pain aggressively (often 
with opiates). That is wrong. Acute pain should 
be treated aggressively but chronic pain is 
different. Patients need to know that there is a 
standard policy of  how physician will deal with 
chronic pain.”
Furthermore, many responses indicated drug 
policy needs to be enacted whereby all prescriptions 
include the diagnosis code. Governmental policy 
comments ranged from increasing oversight, e.g. 
“Benzodiazepines should be made illegal.” to 
decreasing oversight, e.g. “I am not a proponent of  
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the new legislation…vaguely defines ‘chronic pain’ 
in such a way that even acute pain or immediate 
postop pain could fall under that definition and 
that it is therefore too limiting and provides too 
many hoops to jump through for surgeons and their 
practices.” 
Many participants argued for reversing 
JCAHO’s (Joint Commission on Accreditation 
of  Healthcare Organization) “pain as the fifth 
vital sign” policy. Participants discussed the policy 
as setting up a conflicted relationship between 
hospital administrators, providers, and their patients 
pertaining to pain. Additionally, participants felt 
patient’s need to take more accountability. For 
example, one participant stated, “Require patients 
to sign releases allowing us to inform other MDs/
Probation Officers of  their controlled substance Rx 
before initiation of  treatment.” They also spoke of  
requiring pain contracts as a means to hold patient’s 
accountable.
Monitoring
Monitoring comments (n = 715) broke down 
to include ways to improve INSPECT (n = 
319), monitoring system linkages (n = 91), 
and monitoring of  providers (n = 96). Several 
comments suggest ways to improve INSPECT. For 
example, one participant stated, “I wish there were 
an easy way for doctors and pharmacists to flag 
patients’ INSPECT files for obvious drug seeking 
behavior.” Additionally, a number of  participants 
cited problems with INSPECT’s functioning, such 
as “Logging into Inspect site was such a hassle, 
I quit using it.” Indeed a number of  participants 
reflected negatively on requiring a Notary Public for 
INSPECT’s Registration Form. Another participant 
stated, “I like INSPECT, but the software should 
be updated and made more easy to use.” Several 
participants mentioned including additional 
medications as reportable to improve INSPECT; 
for example, “The inclusion of  tramadol and non-
control Acetaminophen containing products (i.e. 
Ultracet, Fioricet) on INSPECT would be helpful.” 
Many participants requested continued linking 
of  INSPECT within the state, e.g. medical records, 
as well as across state prescription monitoring 
programs. Another comment thread considered 
provider monitoring. A participant stated, “I would 
like the state to more closely monitor physicians 
who prescribe large quantities of  narcotics on a 
regular basis.” However, a number of  responses 
also described the need to prevent government and 
law enforcement intrusion into medical practice. 
For example, “Law enforcement (except for a very 
few state agencies) is totally ignorant and for the 
most part needs to stay out of  it unless invited in by 
knowledgeable professionals.” This comment speaks 
to refraining from provider monitoring practices, 
and a minority of  participants’ responses supported 
this assertion. Overall, however, participants support 
monitoring through improvements to INSPECT by 
making it more accessible, user-friendly, linked to 
other monitoring and record-keeping systems, as well 
as judicious and  knowledgeable medical professionals 
guiding oversight of  other medical providers.
Practice
Practice comments (n = 1,183) include suggested 
improvements in screening and evaluation (n = 
178), treatment alternatives including traditional 
mechanisms (n = 208), e.g. mental health and 
substance use treatment, as well as alternative (n 
= 58), e.g. acupuncture and diet/exercise, and 
improving communication between providers as 
well as patient and providers (n = 104). Regarding 
screening and evaluation the overall suggestion was 
to provide “User friendly mental health and addiction 
screening devices.” In terms of  intervention practice, 
a participant stated, 
“Pain management tools for self-care. How 
to cope and adapt to physical limitations from 
chronic pain. Alternatives to medications 
such as hypnosis, acupuncture/acupressure, 
movement modalities. Reframing pain: a 
psychosocial approach to understanding this 
culture that so readily wants to mask pain.”
Finally, speaking to the need for improved 
communication one participant asserted, “A 
COLLABORATIVE educational program with 
pharmacists and physicians on how to best approach 
and control the issue of  abuse and over-prescribing 
of  controlled substances.”  
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CONCLUSIONS
There is a high level of  awareness and knowledge 
of  the INSPECT system.  The majority of  
providers surveyed reported being familiar with 
INSPECT and most who knew about it said they 
used it.  Survey respondents most commonly used 
INSPECT to monitor their patients’ prescriptions, 
particularly those on controlled substances and 
those they believed may be engaging in drug 
seeking behavior.  The most significant barrier that 
respondents encountered in using the system was a 
lack of  time.
Prescribers and dispensers generally agreed that 
INSPECT is an effective tool for monitoring patient 
prescriptions, for decreasing doctor shopping, and 
for decreasing the incidence of  controlled substance 
misuse and diversion.  Similarly, most survey 
respondents agreed that INSPECT data should be 
accessible to law enforcement personnel when they 
are investigating cases related to drug diversion, “pill 
mills”, or other types of  crimes related to the abuse 
of  controlled substances.
Prescribers and dispensers had a wide variety 
of  views about and experiences incorporating 
INSPECT into their clinical practice.  The majority 
indicated that they should not be required to use 
INSPECT and preferred that it be used at the 
prescribers’/dispensers’ discretion.  
Most prescribers familiar with INSPECT 
reported not checking INSPECT prior to writing 
their most recent prescription for a controlled 
substance.  Still, some prescribers and dispensers 
have made modifications in their prescribing and/
or dispensing habits because of  INSPECT with 
most stating that they have reduced the number of  
controlled substances that they prescribe and/or 
dispense.
The respondents also made several important 
recommendations for improving INSPECT and 
reducing the burden of  prescription drug abuse on 
the State of  Indiana:  
•	 Providers would like more ready access to in-
formation regarding prescription drugs, their 
abuse potential, their benefits when treating 
acute pain, and alternatives to drug treatment 
for chronic pain distributed to healthcare loca-
tions.  
•	 Survey participants also indicated that they 
would welcome more continuing educational 
opportunities for prescribers and dispens-
ers regarding a) best clinical pharmacological 
practices; b) regulations and law enforcement 
policies and practices regarding drug diver-
sion; c) current data on trends and patterns of  
prescription drug misuse;  and d) updates on 
current research on treating acute and chronic 
pain.
•	 Respondents indicated that they also would like 
to see a community campaign implemented on 
prescription drug misuse and how to dispose 
of  unused/expired medication.  Our respon-
dents also recommended that the State launch 
and educational initiative targeting providers to 
facilitate  more discussion of  a broader range 
of  pain management options . 
•	 The majority of  the survey participants felt that 
the government should not require prescribers 
to review INSPECT prior to writing a prescrip-
tion for a controlled substance; however, they 
did feel the State should strongly encourage its 
use while also improving access to INSPECT 
and its operational functioning (e.g., moving 
toward “real-time” data reporting).  
•	 Finally, providers would like clear recommenda-
tions for easily administered, comprehensible, 
and affordable screening and evaluation tools 
that detect misuse, distinguish between pre-
scription and illicit drugs, and promote accurate 
histories.
In conclusion, the results of  this survey of  
users suggest that both providers and dispensers 
are strongly supportive and frequent users of  the 
INSPECT program.  The participants’ responses 
indicate that the majority of  users believe INSPECT 
is generally effective and a valuable tool in state-wide 
efforts to reduce the misuse, abuse, and diversion of  
prescription drugs.  While generally very supportive 
of  the program, the respondents also felt strongly 
that use of  INSPECT should be a professional 
decision and not the result of  a government mandate 
and that more could and should be done to expand 
the impact of  the program and to improve the 
system’s operational and technical functionality.
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APPENDIx
Indiana Professional 
Licensing Agency
INSPECT Survey Instrument
Contact:  Harold Kooreman, MA
IUPUI Center for Health Policy
Richard M. Fairbanks School of  Public Health
hkoorema@IU.edu or 317-278-3362
Dear Ladies and Gentlemen:
The Center for Health Policy at the IU Richard M. Fairbanks School of  Public Health at IUPUI is conducting 
a survey of  prescribers and dispensers of  controlled substances to assess attitudes, knowledge, and behaviors 
associated with the Indiana Scheduled Prescription Electronic Collection & Tracking (INSPECT) program.
The survey is being conducted on behalf  of  the Indiana Professional Licensing Agency (IPLA) and the Indi-
ana Attorney General’s Prescription Drug Abuse Prevention Task Force (Task Force).  The questionnaire was 
created in collaboration with members of  the Task Force’s Education Committee.
This survey is completely anonymous, and we will have no ability to track participants’ identities.  Your honest 
responses and feedback are extremely important to us.  The instrument will take approximately 10-15 minutes 
to complete.
My staff  and I will analyze the survey and aggregate the findings.  IPLA staff  and members of  the Task Force 
will not have access to the raw data.  Only aggregated results will be shared with IPLA, the Task Force, and 
the public.  The feedback we receive from those who complete the survey will be used to improve the IN-
SPECT program and assess its impact on the state of  Indiana.
Feel free to contact me if  you have any questions or concerns.  I want to thank you for taking the time to help 
us with this important endeavor.
Sincerely,
Eric R. Wright, PhD
Director, Center for Health Policy
Professor and Chair, Department of  Health Policy and Management
IU Richard M. Fairbanks School of  Public Health at IUPUI
ewright@iu.edu
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Throughout this survey, we will use the following 
important phrases and acronyms:
Controlled prescription medications include all 
drugs classified by the FDA as Schedule II-V:  an 
opiate or opium derivative (e.g., Codeine and 
Morphine), central nervous system depressant (e.g., 
Alprazolam, Clonazepam, and Diazepam) or central 
nervous system stimulant (e.g., Adderall, amphet-
amine, and denzphetamine).
INSPECT (Indiana Scheduled Prescription Electronic 
Collection & Tracking):  Indiana’s prescription drug 
monitoring program.
[Asked of  all respondents]
1.  What best describes your licensure?
○ Medical Doctor (MD)
○ Doctor of  Osteopathy (DO)
○ Doctor of  Podiatric Medicine (DPM)
○ Physician Assistant (PA)
○ Nurse Practitioner (NP)
○ Dentist (DDS or DMD)
○ Pharmacist (Pharm D or Pharm BS)
○ Other (Please specify)
[Asked of  all respondents except Pharmacists]
2.  What best describes your primary practice 
type?
○ Adult
○ Pediatric
○ Both
[Asked of  all respondents except DPMs, Den-
tists, and Pharmacists]
3.  What best describes your primary medical 
specialty? (Check only one response option.  If  
you work in pediatrics, mark your specialty or, 
for General Pediatrics check “Family Medi-
cine”.)
o Addiction Medicine
o Allergy & Immunology
o Anesthesiology
o Cardiology
o Cardiac & Thoracic Surgery
o Critical Care
o Colon & Rectal Surgery
o Dermatology
o Emergency Medicine
o Family Medicine/General Practice
o General Surgery
o Geriatric Medicine
o Hospice & Palliative Medicine
o Hospitalist
o Interventional Radiology
o Internal Medicine
o Neurology
o Neurosurgery
o Nuclear Medicine
o Obstetrics/Gynecology
o Oncology
o Ophthalmology
o Orthopedic Surgery
o Otolaryngology/ENT
o Pain Medicine
o Pathology
o Physical Medicine & Rehabilitation
o Plastic Surgery
o Psychiatry/Mental Health
o Pulmonary Disease
o Radiology
o Radiation Oncology
o Rheumatology
o Sports Medicine
o Urology
o Vascular Surgery
o Other
[Asked of  all respondents]
4. What best describes your primary practice set-
ting (where you see the majority of  patients)?
○ Community Health Center/Public Health 
Clinic
○ Diagnostic Testing Facility
○ Emergency Room
○ Hospital (Inpatient)
○ Long Term Acute Care Hospital
○ Outpatient Clinic (Private Practice or            
Academic) 
○ Outpatient Surgery Center
o Pain Management Clinic
o Pharmacy (Inpatient)
o Pharmacy (Outpatient)
o Rehabilitation Hospital
o Retail Medicine Clinic (CVS Minute Clinic,  
Walgreens Health Clinic, Clinic at Wal-Mart)
o Substance Abuse Treatment Facility (Inpatient
o Urgent Care Facility
o Other (Specify)
[Asked of  all respondents except Pharmacists]
5.  In your practice did you prescribe controlled 
substances in the past 12 months?
○ Yes
○ No
[Asked of  all respondents]
6.  In your practice, did you dispense controlled 
substances in the past 12 months?
○ Yes
○ No
[Asked of  all respondents]
7.  How many years have you been practicing in 
your primary field?
○ Select:  [Range 1-100]
[Asked of  all respondents]
8.  In what county do you practice primarily?
○ Select: [Drop down of  Indiana counties]
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[Asked of  all respondents]
9.  In what zip code do you practice?
○ Select:  [Respondent specify]
[Asked of  all respondents]
10. Do you serve patients residing in another state?
o Yes
o No 
o Unsure 
[Asked of  all respondents who said they served 
patients residing in another state]
11. In what state(s) do they reside? (Check all 
that apply)
o Illinois
o Kentucky
o Ohio
o Michigan
o Florida
o Other (Specify):
[Asked of  all respondents]
12. What best describes your gender?
o Female
o Male
[Asked of  all respondents]
13. In what year were you born?
o Select [Drop down list 1900-present]
[Asked of  all respondents]
14. What best describes your race/ethnicity? 
(Check all that apply)
o American Indian or Alaskan Native
o Asian
o Black/African American
o Hispanic/Latino
o Native Hawaiian/Pacific Islander
o White/Caucasian
o Other (Specify):
[Asked of  all respondents]
15. Before receiving this survey, had you ever 
heard of  the Indiana Scheduled Prescription 
Electronic Collection and Tracking program 
(INSPECT)?
○ Yes
○ No
[Asked of  all respondents who said they had 
heard of  INSPECT]
16. Have you ever used the Indiana Scheduled 
Prescription Electronic Collection and Tracking 
Program (INSPECT)?
○ Yes
○ No
[Asked of  all respondents who had heard of  IN-
SPECT but had not used INSPECT]
17. Why Not? 
o I knew about INSPECT, but didn’t think I 
could use it.
o I knew about INSPECT, but I was told it was 
not applicable to me because of  my license 
type.
o I knew about INSPECT, but I only see inpa-
tients.
o I knew about INSPECT, but I am not con-
vinced it is helpful.
o Other (Please Specify):
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT]
18. Please indicate when you check INSPECT.  
(Check all that apply)
o For new patients prior to prescribing and/or 
dispensing a controlled substance?
o For established patients prior to prescribing 
and/or dispensing a new controlled substance?
o For patients you think may be drug seeking?
o To review your prescribing and/or dispensing 
practices?
o To ensure the accuracy of  submitted data?
o To monitor patients on controlled substances?
o For other reason(s) (Please specify).
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT]
19. How often do you check INSPECT for pa-
tients on controlled substances?
o At every visit
o Periodically
o Never
o At some other interval (Please specify)
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT]
20. When was the last time you visited IN-
SPECT?
o Today
o In the past week, but not today
o In the past month, but not in the past week
o More than a month ago
o Other (Please specify)
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT and had 
prescribed controlled substances in the past 12 
months]
21. The last time you considered writing a 
prescription for a controlled substance, did you 
consult INSPECT?
o Yes
o No 
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[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT and had 
prescribed controlled substances in the past 12 
months and had consulted INSPECT the last 
time they considered writing a prescription for a 
controlled substance]
22. Did the information you learned prompt you 
to change your treatment plan?
o Yes
o No 
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT]
23. In general, what best describes the primary 
reason you visit INSPECT?
o Review a patient’s prescriptions
o Review your prescription practices
o Ensure the accuracy of  submitted data
o To submit controlled substance data
o Other (Please Specify)
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT and had 
prescribed controlled substances in the past 12 
months]
24. For what percent of  patients to whom you 
have prescribed controlled substances did you 
review INSPECT information in the past 30 
days?
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT and had 
prescribed controlled substances in the past 12 
months]
25. For what percent of  patients to whom you 
have prescribed controlled substances did you 
review INSPECT information in the past 12 
months?
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents who had heard of  
INSPECT and had used INSPECT and had 
prescribed controlled substances in the past 12 
months]
26. Consider the patients for whom you have 
reviewed INSPECT in the past twelve (12) month 
period.  For what percent of  these cases did the 
information you obtained from INSPECT alter 
your prescribing decision?
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[All respondents who had prescribed controlled 
substances in the past 12 months]
27. In the past three (3) year period have you 
changed your prescribing practices related to 
controlled substances?
o Yes
o No
[All respondents who had prescribed controlled 
substances in the past 12 months]
28. In the past twelve (12) month period have you 
changed your prescribing practices related to 
controlled substances?
o Yes
o No
[All respondents who had prescribed controlled 
substances in the past 12 months and who had 
changed their prescribing practices either in the 
past 3 years or in the past 12 months]
29. How have your prescribing practices 
changed?
o I prescribe FAR FEWER controlled substances
o I prescribe FEWER controlled substances
o I prescribe MORE controlled substances
o I prescribe FAR MORE controlled substances
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[All respondents who had prescribed controlled 
substances in the past 12 months and who had 
changed their prescribing practices either in the 
past 3 years or in the past 12 months]
30. What factors led you to change your pre-
scribing practices? (Check all that apply)
o Change in my patient mix
o New professional practice standards and pro-
tocols
o Increased professional awareness of  risks, 
benefits, and other solutions
o Increased state or federal guidelines and rec-
ommendations
o Increased law enforcement activity
o INSPECT providing greater access to patient 
prescription drug history
o Increased patient awareness of  risks and ben-
efits
o I am afraid of  legal ramifications
o Increased referrals from other physicians/
providers for treatment of  acute (surgical/
traumatic/short-term) pain patients
o Increased referrals from other physicians/pro-
viders for treatment of  chronic pain patients
o Other (Please specify)
[Asked of  all respondents who had prescribed 
controlled substances in the past 12 months and 
who had changed their prescribing practices ei-
ther in the past 3 years or in the past 12 months]
31. Have the changes you have made in your 
prescribing patterns in the past twelve (12) 
months impacted your ability to help you man-
age your patients’ pain?
o Yes, there has been a POSITIVE IMPACT on 
my ability to help my patients manage their 
pain.
o Yes, there has been a NEGATIVE IMPACT 
on my ability to help my patients manage their 
pain.
o No, there has been NO IMPACT on my abil-
ity to help my patients manage their pain.
[Asked of  all respondents who had heard of  
INSPECT and who prescribed controlled sub-
stances in the past 12 months]
32. In the past twelve (12) month period, do you 
believe that law enforcement and regulatory 
agencies have used INSPECT to monitor your 
prescribing behavior more closely?
o Yes
o No
[Asked of  all respondents who had heard of  
INSPECT and who prescribed controlled sub-
stances in the past 12 months and who believed 
law enforcement was monitoring their prescrib-
ing behavior more closely]
33. Has this caused you to change your prescrib-
ing practices regarding controlled medications?
o Yes
o No
[Asked of  all respondents who had heard of  IN-
SPECT and who had prescribed controlled sub-
stances in the past 12 months and who believed 
law enforcement was monitoring their prescrib-
ing behavior more closely and who had changed 
their prescribing practices regarding controlled 
medications]
34. How have your prescribing practices changed 
due to your perception of  greater oversight?
o I prescribe FAR FEWER controlled substances
o I prescribe FEWER controlled substances
o I prescribe MORE controlled substances
o I prescribe FAR MORE controlled substances
[Asked of  all respondents who had heard of  IN-
SPECT and who had prescribed controlled sub-
stances in the past 12 months and who believed 
law enforcement was monitoring their prescrib-
ing behavior more closely and who had changed 
their prescribing practices regarding controlled 
medications]
35. Has this change in your prescribing practices 
impacted your ability to help your patients man-
age pain?
o Yes, there has been a POSITIVE IMPACT on 
my ability to help my patients manage their 
pain.
o Yes, there has been a NEGATIVE IMPACT 
on my ability to help my patients manage their 
pain.
o No, there has been NO IMPACT on my ability 
to help my patients manage their pain.
[Asked of  all respondents who had dispensed 
controlled substances in the past 12 months]
36. In the past twelve (12) month period have 
you changed your dispensing practices related to 
controlled substances?
o Yes
o No
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[Asked of  all respondents who had dispensed 
controlled substances in the past 12 months and 
who had changed their dispensing practices 
related to controlled substances]
37. How have your dispensing practices 
changed?
o I dispense FAR FEWER controlled substanc-
es
o I dispense FEWER controlled substances
o I dispense MORE controlled substances
o I dispense FAR MORE controlled substances
[Asked of  all respondents who had dispensed 
controlled substances in the past 12 months and 
who had changed their dispensing practices 
related to controlled substances]
38. What factors led you to change your dis-
pensing practices (Check all that apply)
o Change in my patient mix
o New professional practice standards and pro-
tocols
o Increased professional awareness of  risks, 
benefits, and other solutions
o Increased state or federal guidelines and rec-
ommendations
o Increased law enforcement activity
o INSPECT  providing greater access to pa-
tient prescription drug history
o Increased patient awareness of  risks and ben-
efits
o I am afraid of  legal ramifications
o Increased referrals from other physicians/
providers for treatment of  acute (surgical/
traumatic/short-term) pain patients
o Increased referrals from other physicians/pro-
viders for treatment of  chronic pain patients
o Other (Please specify)
[Asked of  all respondents who had dispensed 
controlled substances in the past 12 months and 
who had changed their dispensing practices 
related controlled substances]
39. Have the changes you have made in your 
dispensing patterns in the past twelve (12) 
months impacted your ability to help you man-
age your patients’ pain?
o Yes, there has been a POSITIVE IMPACT on 
my ability to help my patients manage their 
pain.
o Yes, there has been a NEGATIVE IMPACT 
on my ability to help my patients manage their 
pain.
o No, there has been NO IMPACT on my abil-
ity to help my patients manage their pain.
[Asked of  all respondents who had heard of  
INSPECT and who had dispensed controlled 
substances in the past 12 months]
40. In the past twelve (12) month period, do you 
believe that law enforcement and regulatory 
agencies have used INSPECT to monitor your 
dispensing behavior more closely?
o Yes
o No
[Asked of  all respondents who had heard of  
INSPECT and who had dispensed controlled 
substances in the past 12 months and who be-
lieved law enforcement and regulatory agencies 
were using INSPECT to monitor their dispens-
ing behavior more closely]
41. Has this caused you to change your dispens-
ing practices regarding controlled medications?
o Yes
o No
[Asked of  all respondents who had heard of  
INSPECT and who had dispensed controlled 
substances in the past 12 months and who be-
lieved law enforcement and regulatory agencies 
were using INSPECT to monitor their dispens-
ing behavior more closely and who had changed 
their dispensing practices regarding controlled 
medications]
42. How have your dispensing practices changed 
due to your perception of  greater oversight?
o I dispense FAR FEWER controlled substances
o I dispense FEWER controlled substances
o I dispense MORE controlled substances
o I dispense FAR MORE controlled substances
[Asked of  all respondents who had heard of  
INSPECT and who had dispensed controlled 
substances in the past 12 months and who be-
lieved law enforcement and regulatory agencies 
were using INSPECT to monitor their dispens-
ing behavior more closely and who had changed 
their dispensing practices regarding controlled 
medications and who were not Pharmacists]
43. Has this change in your dispensing practices 
impacted your ability to help your patients man-
age pain?
o Yes, there has been a POSITIVE IMPACT on 
my ability to help my patients manage their 
pain.
o Yes, there has been a NEGATIVE IMAPCT 
on my ability to help my patients manage their 
pain.
o No, there has been NO IMPACT on my ability 
to help my patients manage their pain.
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[Asked of  all respondents who had heard of  
INSPECT]
44. What do you perceive as the major barriers 
to using INSPECT in your practice? (Check all 
that apply)
o There are no barriers to using INSPECT in 
my practice
o Insufficient time
o Lack of  reimbursement for additional time to 
use the system
o Lack of  access to computer/internet
o I am not currently registered to use INSPECT
o I am afraid of  legal ramifications
o Other barrier(s) to using INSPECT (Please 
specify)
[Asked of  all respondents who had heard of  
INSPECT]
45. Do you think INSPECT is a useful program 
for (Check all that apply)
o Monitoring prescription histories with regard 
to controlled substances?
o Decreasing the incidence of  “doctor shop-
ping”?
o Decreasing the incidence of  controlled pre-
scription drug misuse?
o Decreasing the incidence of  controlled pre-
scription drug diversion?
o For another reason? (Please specify):
[Asked of  all respondents who had heard of  
INSPECT]
46. Should INSPECT be linked to a national 
controlled prescription medication database?
o Yes
o No
[Asked of  all respondents who had heard of  
INSPECT]
47. Should criminal justice professionals (e.g., 
police, the DEA) be allowed to access IN-
SPECT for patient information?
o Yes 
o Yes, but only under certain circumstances
o No 
[Asked of  all respondents who had heard of  IN-
SPECT and who said criminal justice profession-
als should be allowed to access INSPECT for 
patient information under certain circumstances]
48. Under what conditions should criminal 
justice professionals (e.g., police, the DEA) be 
allowed to access INSPECT for patient informa-
tion? (Check all that apply)
o To identify potential drug diversion for illicit 
purposes
o During the investigation of  an ongoing case 
involving controlled substances
o Yes, under these conditions (Please specify):
[Asked of  all respondents who had heard of  
INSPECT]
49. Should criminal justice professionals (e.g., 
police, the DEA) be allowed to access INSPECT 
to determine if  medical providers are potentially 
overprescribing controlled prescription medica-
tion?
o Yes 
o Yes, but only under certain circumstances
o No 
[Asked of  all respondents who had heard of  
INSPECT and who said criminal justice profes-
sionals should be allowed to access INSPECT 
for medical provider information under certain 
conditions]
50. Under what conditions should criminal 
justice professionals (e.g., police, the DEA) be 
allowed to access INSPECT to determine if  
medical providers are potentially overprescribing 
controlled prescription medications? (Check all 
that apply)
• To identify potential ‘pill mills’
• During the investigation of  an ongoing case 
involving controlled substances
• Yes, under these conditions (Please specify)
[Asked of  all respondents who had heard of  
INSPECT]
51. Should medical professionals be required to 
access INSPECT prior to writing a prescription 
for a controlled medication?
o Yes
o No
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[Asked of  all respondents]
52. How concerned are you about prescription 
drug abuse among the patients in your practice?
o Extremely concerned
o Moderately concerned
o Slightly concerned
o Not concerned at all
[Asked of  all respondents]
53. How concerned are you about prescription 
drug abuse in your community?
o Extremely concerned
o Moderately concerned
o Slightly concerned
o Not concerned at all
[Asked of  all respondents]
54. What percent of  your patients who are tak-
ing controlled prescription medications do you 
feel misuse/abuse the medications (e.g., they 
take more pills in a given time period than pre-
scribed, sell or share their medication or “doctor 
shop” for a provider who will write a controlled 
medication prescription)?  Please provide your 
best estimate.
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents]
55. What percent of  patients in Indiana taking 
controlled prescription medications do you feel 
misuse/abuse the medication (e.g., they take 
more pills in a given time period than pre-
scribed, sell or share their medication or “doctor 
shop” for a provider who will write a controlled 
medication prescription)?  Please provide your 
best estimate.
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents who had dispensed 
controlled substances in the past 12 months]
56. Have you ever refused to dispense a prescrip-
tion for a controlled substance medication?
o Yes
o No
[Asked of  all respondents who had dispensed 
controlled substances in the past 12 months and 
who had ever refused to dispense a prescription 
for a controlled substance medication]
57. In the past year, how many times have you 
refused to dispense prescribed, controlled sub-
stance medication?
○ Select:  [Drop down list from 1-100]
[Asked of  all respondents who had dispensed 
controlled substances in the past 12 months and 
who had ever refused to dispense a prescription 
for a controlled substance medication]
58. For what reasons have you refused to dis-
pense prescribed, controlled substance medica-
tions? (Check all that apply)
○ I could not verify the prescription
○ I believed it would be unlawful
○ I believed it was not in the best interest of  the 
patient
○ I believed it would aid or abet an addiction or 
habit
○ I believed it to be contrary to the health and 
safety of  the patient
○ Fear of  legal ramifications
○ Other (Specify)
[Asked of  all respondents]
59. On average, across all your practice sites, how 
many unique patients do you serve in an average 
month?
○ Specify:  [Respondent specify]
[Asked of  all respondents]
60. Roughly what percent of  your patient revenue 
comes from the following sources? (Categories 
should sum close to 100%)
Medicare  [drop down list 0-100%]
Medicaid   [drop down list 0-100%]
Private insurance  [drop down list 0-100%]
Patient payments  [drop down list 0-100%]
Charity  [drop down list 0-100%]
Research  [drop down list 0-100%]
Tricare  [drop down list 0-100%]
Veterans Administrations [drop down list 0-100%]
Other  [drop down list 0-100%]
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[Asked of  all respondents]
61.a.What percentage of  your patients do you 
estimate are currently prescribed the following 
controlled prescription medications? Opioids 
(pain relievers):
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents]
61.b.What percentage of  your patients do you 
estimate are currently prescribed the following 
controlled prescription medications? Stimu-
lants:
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents]
61.c.What percentage of  your patients do you 
estimate are currently prescribed the follow-
ing controlled prescription medications? CNS 
Depressants:
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents]
62. How often are opioids and benzodiazepines 
prescribed simultaneously for your patients?
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents except Pharmacists]
63. What percentage of  your patients do you see 
for chronic, non-terminal pain?
o 0%  o 51-60%
o 1-10%  o 61-70%
o 11-20%  o 71-80%
o 21-30%  o 81-90%
o 31-40%  o 91-100%
o 41-80%
[Asked of  all respondents except Pharmacists 
who see at least 1% of  patients for chronic, non-
terminal pain]
64. How do you typically manage your patients 
with chronic, non-terminal pain?
o I am comfortable managing these patients 
within my practice.
o I manage these patients within my practice, 
in consultation with other professionals as 
needed.
o I refer all patients with chronic pain medication 
needs. 
[Asked of  all respondents except Pharmacists 
who see at least 1% of  patients for chronic, non-
terminal pain and who do not refer all patients 
with chronic pain medication needs]
65. How often do you use validated mental health 
screening tools, such as the Patients Health 
Questionnaire (PHQ-9, PHQ-2, GAD-7 for anxi-
ety) to screen your chronic, non-terminal pain 
patients for mental health issues before prescrib-
ing opioids?
o Always
o Usually
o Occasionally
o Rarely
o Never
[Asked of  all respondents except Pharmacists 
who see at least 1% of  patients for chronic, non-
terminal pain and who do not refer all patients 
with chronic pain medication needs]
66. How often do you use validated addiction 
screening tools, such as the Opioid Risk Tool 
(ORT), Screener and Opioid Assessment for 
Patients with Pain (SOAPP), or Current Opi-
oid Misuse Measure (COMM) to screen your 
chronic, non-terminal pain patients for potential 
addiction issues?
o Always
o Usually
o Occasionally
o Rarely
o Never
[Asked of  all respondents except Pharmacists 
who see at least 1% of  patients for chronic, non-
terminal pain and who do not refer all patients 
with chronic pain medication needs]
67. What is the maximum morphine equivalent 
dose you will prescribe for chronic non-terminal 
pain patients?
o 100 mg/day
o As much as it takes to relieve their pain or 
improve function
o I don’t consider morphine equivalents when 
prescribing
50
[Asked of  all respondents except Pharmacists 
who see at least 1% of  patients for chronic, non-
terminal pain and who do not refer all patients 
with chronic pain medication needs]
68. Do you personally dispense opioids directly 
to your patients suffering from chronic, non-
terminal pain?
o Yes, routinely
o Yes, infrequently
o No
[Asked of  all respondents except Pharmacists 
who see at least 1% of  patients for chronic, non-
terminal pain and who do not refer all patients 
with chronic pain medication needs]
69. How often do you use urine or other drug 
screening to monitor your chronic, non-termi-
nal pain patients on opioids?
o Always
o Usually
o Occasionally
o Rarely
o Never
[Asked of  all respondents except Pharmacists 
who see at least 1% of  patients for chronic, non-
terminal pain and who do not refer all patients 
with chronic pain medication needs]
70. How do you monitor patient response to 
pain medications? (Check all that apply)
o Patient self-report of  pain alleviation
o Patient self-report of  physical and psychoso-
cial function
o Observation of  physical function
o Other (Please specify)
[Asked of  all respondents]
71.Rank you level of  knowledge of  the medical 
risks of  opioid treatment for chronic non-termi-
nal pain patients.
Low High
○ ○ ○ ○ ○ ○ ○ ○ ○ ○
1 2 3 4 5 6 7 8 9 10
[Asked of  all respondents]
72. Rank your level of  knowledge of  the medical 
benefits of  opioid treatment for chronic non-
terminal pain patients.
Low High
○ ○ ○ ○ ○ ○ ○ ○ ○ ○
1 2 3 4 5 6 7 8 9 10
[Asked of  all respondents]
73. Rank your level of  knowledge of  the medical 
risks/benefits of  prescribing opioids and benzo-
diazepines together.
Low High
○ ○ ○ ○ ○ ○ ○ ○ ○ ○
1 2 3 4 5 6 7 8 9 10
[Asked of  all respondents]
74. What patient information/educational con-
tent, if  any, would help you better care for your 
patients and community?
[Asked of  all respondents]
75. Please include any other comments or addi-
tional information you would like to share.
